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Abbreviations 
Ab     antibody 
ABM    anti-bm12 specific T cells 
Allo    allogeneic 
APC     antigen presenting cell 
ATG    anti-thymocyte globulin 
Bax    Bcl-2-like protein 4 
Bcl-2    B-cell lymphoma 2 
Bcl-xL    B-cell lymphoma-extra large 
BEC    blood endothelial cells 
CCL     chemokine ligand 
CCR     chemokine receptor 
CD    cluster of differentation 
cDNA    complementary deoxyribonucleic acid 
DAMPs   danger associated molecular patterns 
DCs    dendritic cells  
dLNs    draining lymph nodes 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DNCs     double negative cells 
DP    double positive 
ELISA    enzyme-linked immunosorbent assay 
FACS     fluorescence activated cell sorting 
FBS     fetal bovine serum 
FITC     fluorescein isothiocyanate 
Foxp3     forkhead box protein 3 
GATA3   GATA- binding protein 3 
GFP    green fluorescent protein 
GM-CSF   granulocyte-macrophage colony stimulating factor 
GVHD    graft versus host disease 
HBSS     Hanks’ Balanced Salt Solution 
HEV    high endothelial venules 
HSCT    hematopoietic stem cells transplantation 
i.p.    intraperitoneal 
i.v.    intravenous 
ICAM    intercellular cell adhesion molecule 
IDO    indolamin-2,3-dioxygenase 
IFN-    interferon 
IFN-γ     interferon gamma 
IL     interleukin 
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MHC    major histocompatibility complex 
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nTreg    natural regulatory T cells 
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PD-1    programmed cell death 1 
PD-L1    programmed cell death ligand 1 
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PRRs    pattern recognition receptors 
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RT    room temperature 
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SD    standard deviation 
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TCR     T cell receptor 
TGF    Tumor growth factor 
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TNF    tumor necrosis factor 
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Summary 
Solid organs transplantation is therapy of choice for several human diseases. The 
success of this treatment is determined by the recipient’s ability to prevent rejection. 
Rejection is currently controlled by immunosuppressive drugs, which unfortunately have 
side effects for patient quality of life as well as long-term graft survival. It is therefore 
important to better understand the molecular mechanisms underlying tolerance and 
rejection.  
Regulatory T (Treg) cells are known to play an important role in suppressing immune 
responses, and have been demonstrated to be important for establishing allograft 
tolerance. To study Treg-mediated suppression we have generated a skin transplantation 
model in which the transfer of polyclonal Treg cells suppresses anti-Bm12 specific CD4 T 
cells (ABM cells) in a ratio dependent manner. Firstly, we characterized the migration 
pattern of both ABM and Treg cells to the skin graft and to the dLNs. High numbers of 
Treg cells delay the proliferation and reduce the IFN-γ production of ABM cells in the LNs. 
The release of IFN-γ by activated T cells was shown to influence the LN 
microenvironment comprised of stromal cells, which provide a structural environment for 
the homeostasis and differentiation of lymphocytes. Furthermore, T zone reticular cells 
(TRCs) were shown to provide survival factors and negatively regulate activated T cells 
during strong inflammatory responses. We showed that the presence of Treg cells was 
modifying the TRC activity during the establishment of tolerance. TRCs isolated from LNs 
of mice tolerating the graft exhibited enhanced transcription of the chemokines CCL19 
and CCL21, the adhesion molecules ICAM-1 and VCAM-1 and the cytokines TSLP and 
IL-7 compared to TRCs isolated from mice transferred with ABM cells only. In our 
Summary 
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analysis we focused on the survival factor IL-7 and its role in activation. We found that IL-
7 signaling in activated Treg cells leads to further upregulation of the IL-2Rα-chain CD25 
and enhances Treg suppressive capacity in vitro.  
In summary, Treg cells suppress activation and IFN-γ release by effector T cells and 
promote TRC release of IL-7. We hypothesize that TRC derived IL-7 may be required to 
maintain high numbers of Treg cells in the LNs and to prevent skin graft alloresponses. In 
addition, IL-7 might sensitize Treg cells and facilitate their recognition of IL-2, leading to 
Treg cell expansion and better suppression of effector T cell responses.  
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1 Introduction 
1.1 The immune system 
The immune system protects the host against damaging inflammatory responses, which 
occur for example during infection, tumor and autoimmunity. The detection of 
inflammatory responses results in the engagement of innate and adaptive immune 
responses, which act together to efficiently eradicate pathogens and injured cells. While 
innate immunity is rapid and non specific, adaptive immunity is antigen specific and long 
lasting (1) (2).  
1.1.1 Innate immunity 
Innate immunity is highly conserved among different species, underscoring its importance 
for host survival. Innate immune cells, including both professional antigen-presenting cells 
(APCs) (i.e. dendritic cells, monocytes, macrophages and B cells) and non-professional 
antigen presenting cells (i.e. endothelial and epithelial cells), express pattern recognition 
receptors (PRRs). PRRs recognize pathogen and danger associated molecular patterns 
(PAMPs and DAMPs), which induce signal transduction, secretion of cytokines, 
chemokines and other metabolites. The release of these molecules promotes the 
recruitment of immune cells required to resolve the inflammation. While all cells can 
present antigens on major histocompatibility complex (MHC) class I molecules, only APCs 
can engulf and present immunogenic antigens on MHC class II molecules. Maturation 
and activation of innate immune cells are strongly influenced by the recognition via 
different PRRs, including Toll-like receptors (TLRs) and nucleotide oligomerization domain 
Introduction 
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(NOD) receptor family. The maturation of host cells contributes to the activation of 
adaptive immune cells, promotes and mediates cytotoxic response and the development 
of long lasting immunity. In addition to innate cells, the complement system has been 
shown to have an important role during early immune responses. It consists of serum 
glycoproteins that become activated in a cascade sequence with amplification stages.  
1.1.2 Adaptive immunity 
The successful induction of a primary adaptive immune response requires presentation of 
antigenic peptides on MHC molecules to activate naïve T lymphocytes. The majority of T 
cells express a specific T-cell receptor that allows them to recognize cognate antigenic 
peptides displayed by APCs in secondary lymphoid organs (SLO). Antigens are 
processed in cellular compartments and, depending on their localization, are presented 
on MHC class I or II molecules. Cytosolic antigens are presented on MHC class I to 
activate T cells expressing the CD8 co-receptor. Antigens in the degradative 
compartment, including phagosomes and lysosomes, are presented on MHC class II to 
activate T cells expressing the CD4 co-receptor. Activated CD8 T cells have cytolytic 
activity while CD4 T cells support other cells in targeting and eliminating foreign antigens. 
CD4+ T cells, also called T helper cells, can be further subdivided into Th1, Th2, Th17 and 
induced Treg (iTreg) cell subsets. Once activated, adaptive immune cells migrate to the 
inflamed tissue and start an effector response by cell-cell contact and cytokine release. A 
peculiarity of the adaptive immune response is the formation of immunological memory, 
which allows a fast reactivation of antigen-specific T cells after a second exposure to the 
same antigenic peptide.  
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1.1.2.1 T cell selection in the thymus 
To ensure an efficient defense of the host without recognition of self-antigens, 
lymphocytes must be selected during development. Here I will focus on central tolerance 
and T cells selection (3, 4).  
Hematopoietic stem cells in the bone marrow give rise to early thymic precursors that 
migrate to the thymus and develop into mature T cells. The thymus is subdivided into two 
regions; the outer cortex, which contains immature thymocytes and the inner medulla, 
which contains mature T cells. Early thymic precursors are double negative for the co-
receptors CD4 and CD8 and express an unselected αβ TCR repertoire consisting of a 
pre-Tα-chain and a β-chain. The expression of the αβ TCR drives the clonal expansion 
and differentiation of CD4-CD8- thymocytes into CD4+CD8+ double positive (DP) 
thymocytes, which undergo different selection processes.  
In the thymus, 90% of the DP thymocytes express αβ TCRs that fail to recognize the 
peptide-MHC (pMHC) ligand and are therefore eliminated by a process called “death by 
neglect”. The remaining 10% DP thymocytes are either positively selected into the mature 
T cell compartment or eliminated by negative selection. Positive selection occurs when 
thymocytes recognize low affinity antigen in the context of self-MHC while negative 
selection occurs due to strong TCR interactions with pMHC. Negative selection results in 
the elimination of self-reactive T cells and ensures that the peripheral T cell pool is largely 
self-tolerant. Nevertheless, it is clear that some autoreactive T cells escape negative 
selection and enter the periphery where they undergo deletion or anergy induction upon 
encounter with self-antigen. In addition, a more recently identified population of 
CD4+CD25+ regulatory T cells (Tregs) has been demonstrated to exert dominant control 
over the activation of autoreactive T cells.   
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1.2 CD4+ T cells  
1.2.1 T helper cells 
CD4+ T cells arise in the thymus from single positive CD4+CD8- precursors. Once they 
migrate to the periphery they recognize antigens presented on MHC class II molecules 
expressed by APCs. Depending on the activation state of the APCs and the cytokine 
environment present at the time of antigen encounter, CD4+ T cells can differentiate into 
four major subsets: Th1, Th2, Th17 and iTreg cells (5-8) (Fig. I).  
  
Figure I. Differentiation of T helper cell subsets (as reviewed in (8, 9)). Particular cytokine 
environments differentiate naïve CD4 T cells into different subsets (Th1, Th2, Th17, iTreg) 
that have distinct function in the regulation of immune responses. Each subset is 
characterized by a specific transcription factor (T-bet, GATA3, ROR-γt and FoxP3).  
Th1 cells develop in response to IL-12, produced by macrophages and APCs upon 
encounter with several microbial products, and IFN-γ, produced by Th1 cells in a positive 
feedback loop (5, 8, 9). They are characterized by the expression of the transcription 
TH1
TH2
TH17
iTreg
FoxP3
Tbet
GATA3
RORγT
Tnaive I
L-1
2 / 
IFN
γ
TGF-β / IL-6
IL-4 
IL2, TSLP
TGF-β / IL-2
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factor T-bet and the signal transducer and activator of transcription (STAT) molecule 
STAT4. Th1 cells secrete IL-2, IFN-γ and tumor necrosis factor-beta (TNF-β) and activate 
macrophages to kill engulfed pathogens and recruit other immune cells to the site of 
infection. Indeed, Th1 cells are responsible for cell-mediated immunity against 
intracellular pathogens. However, these cells need to be strongly controlled since they 
have been also implicated in the immunopathology of certain organ-specific autoimmune 
diseases (10-13). In addition, unwanted Th1 responses against donor-antigens are an 
obstacle to successful graft tolerance following organ transplantation (14).  
Th2 differentiation is driven mainly by IL-4 (15) and TSLP (16-18) and is characterized by 
the expression of GATA3 and activated STAT5, which promote gene transcription of IL-4, 
IL-5, IL-9, IL-13 and IL-25 cytokine genes. Th2 responses regulate the elimination of 
extracellular pathogens and antibody-mediated immunity, by attracting and activating 
eosinophils and basophils, and by promoting the synthesis of IgE antibodies (9).  
Th17 responses differentiate in the presence of TGF-β and IL-6 and are characterized by 
the ROR-γt transcription factor and STAT3 activation. Through the production of IL-17 
and IL-22, Th17 cells control immune responses against extracellular bacteria and fungi.  
iTreg cells differentiate in the presence of TGF-β and IL-2 and express factor forkhead 
box P3 (FoxP3) and STAT5. iTreg cells maintain peripheral immune tolerance and regulate 
immune responses (9).  
Importantly, the cytokine production of each subset negatively regulates the other to 
ensure only one polarization of the immune response under specific conditions (5). 
1.2.1.1 T cell migration in vivo 
The continuous migration of T cells within the body is regulated through various adhesion 
and activation events that occur between T cells and the vascular epithelium. T cells from 
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the blood enter the LN via specialized high endothelial venules (HEVs). In the LN, naïve 
and memory T cells scan for antigens before returning to the circulation via the 
lymphatics. In contrast to steady state conditions, inflammatory signals and activated 
DCs increase the recruitment to the LN by inducing chemokines and adhesion molecules 
(19). The interactions between adhesion molecules of the vascular endothelium and the 
activated T cells signal to induce firm arrest which facilitates the entry into the LN and 
other tissues (20). Naïve CD4+ T cells express high levels of the L-selectin adhesion 
molecule (CD62L) that binds to the glycosylation-dependent cell adhesion molecule 1 
(GlyCAM-1) expressed on HEVs of the LNs (21). This interaction is fundamental for T cell 
homing to SLOs since it allows the firm adhesion and rolling of free-floating T cells on 
HEVs. Subsequently, the expression of the chemokine receptor 7 (CCR7) on T cells is 
important for the transmigration after binding with chemokine-ligand 19 (CCL19) and 
chemokine-ligand 21 (CCL21) expressed on HEVs and within the LNs (22). CCR7 
signaling activates integrins such as lymphocyte function-associated antigen-1 (LFA-1) 
and very late antigen-4 (VLA-4) on T cells to facilitate binding on intercellular adhesion 
molecule-1 and 2 (ICAM-1/2) and vascular cell adhesion molecule-1 (VCAM-1) 
respectively to transmigrate through the HEVs (23). All of these adhesion molecules are 
not only involved in cell arrest for proper migration but also have an important role in the 
formation and stabilization of immunological synapses during T cell priming (24).  
T cells egress from the LN and other SLOs depends on the expression of the 
sphingosine-1-phosphate receptor 1 (S1P1) in response to high concentration of the S1P 
ligand present in the lymph and blood (25). Once back in the circulation, other chemokine 
receptors guide activated T cells to inflamed tissues. In particular the chemokine receptor 
CCR4 is required to drive the migration of T cells to inflamed skin (26).  
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1.2.1.2 Costimulatory molecules influencing TCR signals  
T cell activation leads to the up-regulation and down regulation of various surface 
molecules involved in effector function and recognition of microenvironmental signals. 
CD69 is a surface glycoprotein (27) known as early leukocyte activation molecule and 
acts as a costimulatory molecule for T-cell activation and proliferation (28). In addition, 
CD69 was described to inhibit the function of S1P1 (29), and to have an 
immunomodulatory role in down regulating immune responses through the production of 
TGF-β (30). CD44 is a cell-surface glycoprotein that binds to extracellular matrix 
component via the glycosaminoglycan hyaluronic acid (HA). Effector and memory T cells 
upregulate CD44 (31), which in turn modulates growth, survival, differentiation and 
motility (32). CD44 has also been shown to regulate the recruitment of inflammatory T 
cells to the skin by binding to E-selectin on the skin endothelium (33, 34). While naïve T 
cells express high levels of the IL-7 receptor (IL-7R) (35), activated T cells express the IL-
2 receptor (α-chain) CD25 (36) (see Chapter 1.2.1.3). 
In addition, inhibitory molecule including programmed cell death 1 (PD-1) and T cell 
immunoglobulin and mucin domain-3 protein (TIM-3) are expressed on fully activated 
effector Th1 cells and define the phenotype of exhausted effector T cells (37-39). PD-1 
interacts with two possible ligands: PD-L1, which is expressed on leukocytes and non-
hematopoietic cells, and PD-L2 that is expressed exclusively on dendritic cells and 
monocytes (40-42). Engagement of PD-1 by either of its ligands during TCR signaling 
block T-cell proliferation, cytokine production, cytolytic function and impair T-cell survival 
by preventing the induction of the survival factor Bcl-xL and the expression of T cells 
subsets-specific transcription factors (37, 43). In particular, PD-1/PD-L1 interaction was 
shown to promote tolerance by increasing T cells mobility and preventing stable 
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conjugates between T cells and APCs (42). TIM-3 is expressed on a variety of cells 
including activated DCs, Treg cells and Th1 cells. Once an effector Th1-cell response �is 
generated, terminally differentiated Th1 cells express TIM-3, which then upregulate the 
expression of the TIM-3 ligand, galectin-9, through the production of IFN-γ. Finally, 
galectin-9 binds TIM-3 on the surface of Th1 cells and inhibits their response by triggering 
cell death (38, 44). Blocking the TIM-3 pathway results in hyperproliferation of Th1 cells 
with massive IFN-γ production and abrogates allotolerance (39, 45). Indeed, both PD-1 
and TIM-3 molecules activate signaling pathways which are important for the termination 
of immune responses. 
1.2.1.3 Survival and proliferation signaling in T cells 
Common cytokine receptor γ-chain (γc) family cytokines have crucial roles in the 
development, proliferation, survival and differentiation of different cell linages. The 
receptors for those cytokines share the γc that form dimers or trimers with cytokine-
specific chains (46). Here I will focus on IL-7 and IL-2 signaling. 
IL-7 is produced mainly by stromal cells, epithelial cells and fibroblasts and has a central 
role in the development of T cells in both human and mice (47, 48). Abrogation of IL-7 
signaling leads to severe defects in T cell development and lymphopaenia (49). In 
addition, IL-7 was shown to be involved in LN organogenesis (50) and is recognized as a 
potent lymphocyte survival factor in the periphery (51, 52). IL-7 signals through the IL-7R, 
which consist of a dimer formed between the γc and the IL-7R α-chain (Fig. II). IL-7 
signaling is important for the induction of B-cell lymphoma 2 (Bcl-2) molecule, which 
prevents apoptosis in T cells (53, 54). Indeed, Bcl-2 overexpression rescued IL-7R-
deficient T cells (55, 56) and partially but not completely restored T cell numbers and 
function. These data suggest an additional role for IL-7 and IL-7R signaling beyond Bcl-2 
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induction. Indeed, IL-7 was shown to play a key role in preventing atrophy and 
maintaining resting T cells metabolism (57).  
Interestingly, the IL-7R α-chain is shared by an IL-7-like cytokine, thymic stromal 
lymphopoietin (TSLP) although it does not belong to the γc family (58). Indeed, the TSLP 
receptor consists in the IL-7R α-chain in combination with the TSLPR which is closely 
related to the γc chain (Fig. II). TSLP was described to be preferentially expressed by 
epithelial cells within different tissues, including lung, skin and gut (58). In the periphery, 
TSLP is mainly described to be involved in the generation of Th2 responses by 
modulating DCs (16-18, 58). In the thymus, the release of TSLP by human thymic 
epithelial cells activates a subpopulation of DC to express CD80 and CD86, which may 
be critical for the differentiation of auto-reactive T cells into Treg cells (59). 
In addition to the survival factor IL-7, IL-2 is an important cytokine produced by activated 
T cells which is required for T cells growth and proliferation. Moreover, IL-2 is essential for 
Treg cells expansion and mice deficient in IL-2 signaling have severe autoimmune 
disorders (60). IL-2 signals via the trimeric IL-2R, which consist of the γc together with IL-
2R α- and IL-2R β-chains (Fig. II). Both IL-7R and IL-2R activate signal transduction 
pathways that involve the tyrosine kinases Janus kinase 1 (JAK1) and JAK3 and mainly 
the STAT molecule STAT5 (46). TSLPR in combination with IL-7Rα activates Jak1, Jak2 
and STAT5. Inhibitory molecules like PD-1 can inhibit STAT5 phosphorylation and 
therefore negatively affect T cells proliferation and survival (61). 
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Figure II. IL-7, TSLP and IL-2 receptors and signal transduction (adapted from (46)). 
Dimeric IL-7 and TSLP receptor and the trimeric IL-2 receptor are represented. The major 
signal transduction molecules are represented and the main signal transducer and activator 
of transcription (STAT) protein STAT5 is shown in bold. 
 
1.2.2 Regulatory T cells 
1.2.2.1 Definition, phenotype 
To function properly, the immune system must discriminate between self and non-self; 
when this discrimination fails, the immune system destroys cells and tissues of the body 
and as a result causes autoimmune disease. Regulatory T (Treg) cells are a specialized 
subpopulation of CD4 T cells that suppress the activation of the immune system, thereby 
maintaining immune homeostasis and tolerance to self-antigens (62). 
Treg cells are traditionally defined as CD4+ T cells that constitutively express the α-chain 
of the IL-2 receptor, CD25. Furthermore, they constitutively express the transcription 
factor forkhead box P3 (FoxP3) which can be used for their identification and isolation 
and is required for their development (63) and suppressor function (64). Mice that carry a 
spontaneous loss-of-function mutation or deletion of the FoxP3 gene, known as scurfy 
JAK2JAK1
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mice, develop an autoimmune-like disease with hyper-responsive CD4+ T cells. These 
data underscore the importance of Treg cells in the maintenance of peripheral tolerance 
(65).  
Treg cells can arise via two distinct developmental pathways. Naturally occurring Treg 
cells (nTreg) are selected in the thymus. They represent 5% of mature CD4+CD8- 
thymocytes (66) and 5-10% of the CD4+ T cells in the periphery (67). Since they are 
selected by autoantigens, they express a high affinity autoreactive TCR repertoire (67) 
that allows to suppress immune responses to self antigens in the periphery and thereby 
prevent autoimmunity (68, 69). Alternatively, CD4+ T cells that are activated by antigens in 
the periphery in a tolerogenic microenvironment can develop into induced Treg cells 
(iTreg) that also express high levels of the transcription factor FoxP3 (70). Interestingly, 
FoxP3 expression on iTreg was shown to be unstable compared to the expression on 
nTreg, which is probably related to the different methylation of the FoxP3 locus in the two 
Treg populations (71). The conversion from effector T cells to iTreg cells requires TCR and 
CD28 signaling and specific cytokines, like TGF-β and IL-2 (68). The microenvironment, 
therefore, plays a fundamental role in the generation of iTreg cells from effector cells in 
order to prevent destructive immune responses.  
1.2.2.2 Suppressive mechanism  
The molecular mechanism by which Treg cells exert their suppressor/regulatory activity 
has not been definitively characterized and is the subject of intense investigation. Four 
main mechanisms have been proposed (Figure III).  
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Figure III. Treg cells suppression mechanisms (72). (A) Inhibitory cytokine suppression via 
IL-10, IL-35 and TGF-β. (B) Cytolysis of target cells via granzyme A or B and perforine. (C) 
Metabolic disruption of IL-2 via high expression of CD25 and of adenosine via expression of 
CD39 and CD73. Cyclic AMP (cAMP) transfer in the target cells through gap junction inhibit 
IL-2 production. (D) Suppression by targeting and impairing maturation and function of DCs. 
Treg cell can produce inhibitory cytokines including IL-10, IL-35 and transforming growth 
factor β (TGF-β) that directly act on effector T cells to suppress a wide spectrum of 
cellular activities (Figure III, A). IL-10 strongly inhibits the establishment of Th1 responses 
and the activation of APCs leading them to a tolerogenic phenotype. IL-35 and TGF-β are 
strong inhibitors of T cell proliferation. In addition TGF-β is involved in the maintenance of 
nTreg and the induction of iTreg creating a tolerogenic environment (73).  
Treg cells have been shown to induce cytolysis of NK and CD8 T cells in tumors in a 
granzyme B- and perforin dependent fashion upon activation (Figure III, B). Interestingly, 
A  Inhibitory cytokines B   Cytolysis
C  Metabolic disruption D   Targeting dendritic cells
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the cytotoxic activity of Treg cells was induced by the tumor environment and the 
deficiency of granzyme B resulted in successful clearance of tumor cells (74).  
Treg cells can exert metabolic disruption as another suppressive mechanisms (Figure III, 
C). As mentioned before, Treg cells constitutively express the α-chain of the IL-2 
receptor, CD25 that allows them to consume the IL-2 in the surrounding environment. 
Since Treg cells are unable to produce IL-2, they must compete for IL-2 produced by 
activated T cells and in doing so, actively starve dividing cells and deprive them from this 
essential survival factor (75, 76). In addition, it was shown that the pericellular 
accumulation of adenosine elicits immunosuppressive cellular responses (77). The 
extracellular adenosine is generated by two important ectoenzymes that are expressed on 
the surface of Treg cells, CD39 and CD73. CD39 hydrolyzes adenosine tri- and 
diphosphate (ATP and ADP) to adenosine monophosphate (AMP). Extracellular AMP is, in 
turn, rapidly degraded to adenosine by CD73. The accumulation of pericellular adenosine 
can elicit immunosuppressive cellular responses by the interactions with the adenosine 
receptors (A2AR) expressed on activated T cells (77). Moreover, Treg cells harbor high 
levels of cyclic AMP (cAMP) that via gap junctions can be directly transferred into effector 
T cells leading to inhibition of proliferation and IL-2 synthesis (78).  
Treg cells were shown to suppress the maturation and function of DCs (Figure III, D). 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) interacts with co-stimulatory molecules CD80 
and CD86 on DCs that impair the priming of effector T cells and induce indoleamine 2,3-
dioxygenase (IDO) production. IDO is known to be a potent regulator of effector functions 
by inducing the production of pro-apoptotic metabolites from the catabolism of 
tryptophan (79). On the other hand, lymphocyte-activation gene 3 (LAG3) expressed on 
Treg cells binds with high affinity the MHCII molecule on DCs and, by activating inhibitory 
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signaling pathways, suppresses DC maturation and their immunostimulatory capacity 
(80).  
1.2.2.3 Regulation of homeostasis and suppressive capacity of Treg cells  
While IL-2 was shown to be the main factor involved in intrathymic Treg cells 
development, IL-7 mediates Treg cell development in the absence of IL‐2 (81-83).  
Similarly, IL-2 was shown to be important for peripheral homeostasis (60, 84) and 
suppressor function of Treg cells (76). Indeed, mice deficient for IL-2 or IL-2R showed a 
decreased number of Treg cells in the thymus and periphery leading to autoimmune 
diseases (60). Naïve CD4+ T cells and memory T cells have been shown to rely on IL-7 for 
their peripheral homeostasis (35, 85). However the role of IL-7 in the homeostasis of Treg 
cells is still unknown. In the last years, several studies reported that Treg cells express IL-
7R (86-88) and require IL-7 for their homeostatic proliferation (86, 88). Whether IL-7 is 
important for Treg cells function is still not known.  
In addition to environmental factors, cell-cell contact molecules might influence Treg cells 
activity. The PD-L1 expression on non-hematopoietic and hematopoietic cells in the 
presence of TGF-β promotes the de novo generation of Treg cells (37). The negative 
costimulation receptor PD-1 was shown to be expressed on Treg cells and it was recently 
reported that Treg cells from PD-1 KO mice were unable to suppress CD8 T cell 
responses against tumors (89). Interestingly, Treg cells also express PD-L1, which seems 
to have important implications in the maintenance of high Treg numbers and possibly the 
generation of additional iTreg cells (37).  
Recently a new PD1+ Treg population was identified by coexpression of TIM-3 in skin 
graft at the time of rejection (90). PD1+ Treg cells exhibited higher in vitro effector function 
and an increased suppressive capacity following skin transplantation. However, TIM-3+ 
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Treg cells did not proliferate when transferred into newly transplanted host providing 
evidence that they are a short-lived Treg cell population.  
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1.3 The lymph node  
Lymph nodes (LNs) are SLO with a highly organized structure and are located at the 
points where vessels of the lymphatic system converge. The LN consists of a capsule 
containing an outer cortex and an inner medulla. The cortex can be subdivided into 
different areas. The outer part consists of B cells organized in primary or secondary 
lymphoid follicles that contain the germinal centers where B cells proliferation occurs 
during an immune response. The inner paracortical area contains mostly T cells and 
dendritic cells. Macrophages and plasma cells are present in the medulla and make up 
the inner medullary cords (1). A dense network of reticular fibers maintains this 
compartmentalized structure with functionally different microenvironments. Follicular 
dendritic cells (FDCs) (91, 92) are present in the B cell zone and produce CXCL13 to 
attract and retain B cells, while CCL19 and CCL21 produced by T zone reticular cells 
(TRC) exert the same function for T cells and antigen presenting cells (APCs) (Figure IV). 
Lymph draining from extracellular spaces of the body enters through the afferent 
lymphatic vessels located beneath the capsule (subcapsular sinus) and exit the LN via the 
efferent lymphatics in the medulla. Lymphocytes recirculating in the blood are able to 
directly enter the LN through specialized blood vessels known as high endothelial venules 
(HEVs) (93). These specialized post-capillary venules are composed by plump endothelial 
cells which constitutively express adhesion molecules and chemokines at their luminal 
surface thereby allowing the continuous transmigration of lymphocytes (94). 
Similar to other SLO, LNs fulfill three major functions in the body. First, they filter 
extracellular fluids from the tissues to sample antigens, PAMPs and DAMPs present in the 
body. Second, they are the organs where adaptive immune responses are initiated. APCs 
from infected tissues migrate to the LN where they encounter and prime naïve immune 
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cells coming from primary lymphoid organs, thymus and bone marrow. Third, LNs provide 
a structural environment for the homeostasis and differentiation of lymphocytes.  
1.3.1 Lymph node stromal cells 
1.3.1.1 Localization, phenotype and characterization 
Lymph node stromal cells (LNSC) are non-hematopoietic mesenchymal cells with 
fibroblast properties that form the architectural scaffold of the LN. By creating a 
specialized conduit system, LNSC facilitate and ensure an efficient T cells encounter and 
crosstalk with APCs (95-99). Recently, four different LNSC subsets have been identified 
by the expression of the adhesion molecule CD31 (PECAM-1) and the glycoprotein 
podoplanin (gp38). T zone reticular cells (TRC, also known as follicular reticular cells 
(FRC)) are gp38+CD31-. Lymphatic endothelial cells (LEC) are gp38+CD31+. Blood 
endothelial cells (BEC) are gp38-CD31+, and a fourth population is double negative (DNC) 
for both markers (97) (Figure IV).  
LECs and BECs surround lymphatic and blood vessels respectively and regulate the 
migration of immune cells into and out of lymph nodes by the expression of chemokines 
and adhesion molecules. LECs have recently been described to be involved in peripheral 
tolerance by direct presentation of peripheral tissue antigens (PTA) to CD8 T cells. As a 
result, autoreactive CD8 T cell proliferation is inhibited and CD8 T cells can be deleted 
due to both a lack of costimulation and active PD-L1 engagement (100). Less is known 
about the function of the DNC subset. Although DNCs closely resemble TRCs in their 
gene expression profile they have recently been described to contain pericyte-like cells 
with highly contractile function (101). These cells express the highest level of α-smooth 
muscle actin (α-SMA) transcripts and over half of them are positive for integrin α7 
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(ITGA7). For this reason, they have been newly termed “ITGA7+ pericytes” (IAPs). Recent 
data indicate that DNCs surround some of the medullary and cortical vessels (101) and 
are suggested to be important for the expansion and contraction of vessels during 
immune responses (confidential data from A. Fletcher, AAI Conference 2012). TRCs are 
the major LNSCs and secrete extracellular matrix components to form a dense reticular 
network and the lymph draining conduit system (95, 102). Furthermore, they have been 
shown to both positively and negatively influence immune responses (101, 103-105). 
 
 
Figure IV. Location of lymph node stromal cells in the LN (adapted from (106)). (A) 
Follicular dendritic cells (FDCs) are located in B cells follicles. (B) Lymphatic endothelial cells 
(LECs) surround lymphatic vessels. (C) T zone reticular cells (TRCs) networks are found in T 
A B
C D
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cell zones in the paracortex of the lymph node where T cells and DCs encounter each other. 
(D) Blood endothelial cells (BECs) form specialized blood vessels known as high endothelial 
venules (HEVs) which are surrounded by a perivascular sheath and a basal lamina. (E) TRCs 
produce the chemokines CCL19 and CCL21 to attract and guide T cells and DCs along the 
three-dimensional network. (F) TRCs produce the cytokine IL-7 to promote naïve T cells 
survival. 
1.3.1.2 TRCs as positive regulators of T cell responses  
TRCs have been shown to positively regulate T cells responses by various mechanisms. 
Once T cells enter the LN via the HEVs they immediately associate with and crawl along 
the TRC network which functions as a local road to define the path of T cell migration 
within the LN parenchyma. TRCs might facilitate T cells in their search for cognate 
antigens presented by DCs colocalized to the same TRC network. In addition, since TRCs 
are almost exclusively present in the paracortex and naive T cell movement is largely 
restricted to the TRC network, the latter also defines the T cell zone in the LN and is likely 
to play a key role in preventing naive T cell entry into B cell follicles (95, 96). Both the 
migration and the confinement in these regions of the LN are dependent on the secretion 
of specific chemokines. Indeed, TRCs are the main constitutive producers in the LN of the 
homeostatic cytokines CCL19 and CCL21 that are recognized by CCR7 molecules 
expressed on the surface of incoming naïve T cells and dendritic cells (Figure IV, E). The 
lower average motility and velocity of adoptively transferred CCR7-deficient CD4+ T 
lymphocytes observed in T cell zones of wild type (wt) recipients (107) confirmed the 
central role of CCR7 receptor signaling in enhancing these processes (108, 109). 
Moreover, CCL19 has been shown to play an important role not only in the motility but 
also in the survival of naïve T cells (97) as well as in the maturation of dendrite formation 
and antigen uptake by dendritic cells (105, 110, 111). 
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TRCs are the main local source of IL-7 in the LN (97) (Figure IV, F). IL-7 is a stromal-cell 
derived cytokine that has important function during LN organogenesis (50). In addition, IL-
7 regulates lymphocyte development in bone marrow and thymus as well as naïve and 
memory T cells homeostasis in the periphery (51) by modulating T cell fitness and 
survival. Indeed, during HIV-1 infection, loss of the FRC network and access to IL-7 leads 
to the apoptosis of naïve T lymphocytes (112). In addition, IL-7 seems to have an 
important role in enhancing TCR signaling and primary antigen-specific T cell expansion 
(113, 114). Within the LN, IL-7 does not diffuse freely but is immobilized by extracellular 
matrix components (115). This allows the local provision of highly concentrated IL-7 to 
cells trafficking through the LN and defines a constrained niche for naïve cells and 
memory cells (115, 116). In addition, IL-7 was shown to be involved in LN remodeling 
following viral infection in both humans and mice (117). 
1.3.1.3 TRCs as negative regulators of T cell responses  
Many recent studies have reported the negative impact of TRCs on immune responses. 
Similar to BEC and LEC, TRCs have been shown to express peripheral tissue antigens 
(pTA) (103, 118-121), suggesting an important role for LNSC in the establishment of CD4 
and CD8 peripheral T cell tolerance. The expression of inducible nitric oxide synthase 
(iNOS) depends on nitric oxide (NO) production by TRCs and is a key molecule in down 
regulating T cells expansion and tolerance induction (118, 121). Besides their role in 
promoting tolerance, TRCs are also important for dampening acute T cell immune 
responses (104, 120, 122). Although TRCs do not affect initial T cell priming, they exert 
control over the survival and proliferation of activated T cells (105). NO has a central role 
also in this process and is released by TRCs after synergistic IFN-γ and TNFα stimulation 
(104, 120). Activated CD8 T cells produce these cytokines in the LN less then 24h after T 
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cell priming. NO is a free radical that is rapidly captured by neighboring cells and 
negatively regulate T cells by different mechanism. In human it was shown to down 
regulate the TCR complex by nitrosylating diverse amino acid residues (123). In addition, 
the consumption of the iNOS substrate L-arginine down regulates the ζ chain of the TCR 
and inhibits T cell proliferation (124). NO was shown to block the phosphorylation of the 
“signal transduction and transducer 5” (STAT5) thereby interfering with IL-2 signaling and 
production by activated T cells (125).  
Another IFN-γ-dependent suppressive mechanism is mediated by programmed cell death 
ligand 1 (PD-L1). PD-L1 is up-regulated on TRCs as well as on LECs (126) during acute 
immune responses (104, 120). The interaction of PD-L1 with the receptor PD-1 expressed 
by activated T cells blocks early activation signals promoted by CD28 and up-regulation 
of the high affinity IL-2 receptor (37, 126). Moreover, PD-1 engagement prevents the 
induction of the cell survival factor Bcl-xL as well as expression of transcription factors 
associated with T cell effector function and appears to promote the development and 
function of Treg cells (37).  
IFN-γ was shown to be the major regulator of FRC activity. Thus, IFN-γ exhibits both 
positive and negative influences on immune responses.  On the one hand, IFN-γ acts as a 
pro-inflammatory cytokine that promotes macrophage activation, clearance of 
intracellular pathogens, up-regulation of MHC molecules and promotion of T-helper 1 
(Th1) responses.  On the other hand, IFN-γ also limits tissue disruption by interrupting 
immune responses that are too strong (105). 
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1.4 Transplantation 
Organ transplantation is the surgical operation by which a failing or damaged organ in the 
recipient is substituted with a healthy organ from the donor. In 1954 Joseph Murray 
performed the first successful kidney transplantation on identical twins (127). Nowadays 
transplantation is an important medical intervention and can be performed for different 
organs, and tissues. There are different transplantation types: autografts are transplants 
within the same individual; syngrafts and allografts are transplants from genetically 
identical and genetically unrelated individuals respectively.  
1.4.1 MHC restriction 
The discovery of MHC restriction shed light on the phenomenon of rejection of MHC 
mismatched organs and tissues (1). Positive T cell selection in the thymus and bone 
marrow restricts T cell recognition of MHC. Following migration to the periphery, T cells 
recognize peptides presented only by self-MHC molecules.  However, when T cells 
encounter peptide presented by non-self MHC (i.e. MHC present in the transplanted 
organ), they undergo an alloresponse characterized by strong proliferation and effector 
differentiation. Even when donor and recipient are completely MHC matched, an 
alloresponse may occur due to minor histocompatibility antigens, protein from the grafted 
tissues that are presented to T cells. Allogeneic T cells are the main players in transplant 
rejection.  
1.4.2 Direct and indirect allorecognition 
A critical event in the rejection of a grafted organ is the presentation of donor alloantigens 
by DCs that migrate from the graft to the draining LNs to initiate T-cell priming and 
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differentiation into effector cells. Alloantigens can be presented to the recipient T cells in 
two ways (128). In the first phase, resident donor DCs migrate from the graft to draining 
LN (dLNs) where they activate specific T cells that recognize intact donor MHC 
molecules. In the second phase, recipient DCs process and internalize donor MHC 
antigens in the graft and then migrate to dLNs to present donor Ag on self-MHC 
molecules to recipient T cells (128).  
1.4.3 Different types of rejection 
Donor organs can be rejected early or late after transplantation (1). Hyperacute rejection 
is caused by preexisting alloantibodies present in the recipient at the time of 
transplantation. This process can happen within minutes. An acute rejection occurs within 
weeks after engraftment and is driven by activation of allogeneic T cells. However, 
engraftment of organs does not lead to life long acceptance and transplanted organs can 
still be rejected in a process called chronic rejection. The major cause for chronic graft 
rejections is progressive atherosclerosis, fibrosis and athrophy of blood vessels, which 
normally supply the grafted organ. Furthermore, infections and activation of immune 
responses might change the microenvironment and break established tolerance. 
1.4.4 Transplantation treatments in the clinics 
To avoid rejection of the transplanted organ, patients must take lifelong 
immunosuppressive drugs, which can have serious side effects. It is therefore of primary 
interest to find new immunological targets to reduce immunosuppression and improve the 
quality of life of transplanted patients.  
One of the main strategies used to promote allograft acceptance is the administration of 
lymphodepleting agents. Paradoxically, depletion of lymphocytes may predispose the 
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recipient to reject the transplanted organ by promoting the development and expansion 
of alloreactive memory T cells (116). Indeed, following depletion, remaining adaptive 
lymphocytes undergo homeostatic proliferation in order to repopulate the peripheral 
lymphoid compartment. During this process T cells acquire a memory-like phenotype and 
the ability to respond to low doses of antigen, even in the absence of costimulation. 
These cells would therefore become more dangerous because more resistant to depletion 
and costimulation blocking treatments (116, 129). The combination of depleting 
approaches with therapies that sustain the development and expansion of Treg cells 
would be the best strategy in treating allograft rejection.  
The fate of an alloimmune response is dependent on the balance between alloreactive 
effector T cells and Treg cells in vivo (130).  
In recent years thymoglobulin, a rabbit polyclonal anti-thymocyte globulin (ATG) widely 
used for induction therapy in clinical transplantation, was shown to prolong graft survival 
by depleting peripheral T cells and preferentially sparing natural Treg cells (131). This 
treatment thereby limits the generation of dangerous alloreactive cells arising after 
homeostatic proliferation (132).  
Furthermore, many transplant recipients are nowadays treated with a monoclonal 
antibody specific for CD25, the IL-2 receptor α chain. However both activated effector T 
cells and Treg cells express high levels of CD25 making them susceptible to this 
treatment. For this reason the impact of the anti-CD25 antibody administration on the 
generation and expansion of Treg cells is still under debate (70).  
Rapamycin is a well known immunosuppressive drug that targets the mammalian target 
of rapamycin (mTOR) pathway that has been shown to sustain both Treg cell generation 
ex vivo (133, 134) and function in vivo (135).  
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1.4.5 Clinical Treg cells therapy 
In addition to immunosuppressive therapies that promote Treg cells induction in vivo, 
patients may also be treated with an infusion of Treg cells shortly before transplantation 
or during an acute rejection episode (136). Ex vivo expanded thymic-derived Treg cells 
were shown to clinically improve two patients that developed graft versus host disease 
(GVHD) after bone marrow transplantation (137). An alternative treatment for patients with 
chronic GVHD is low-dose IL-2 therapy (138) which was shown to increase the median 
number of Treg cells.  
There are two main concerns with the use of Treg therapies in the clinics. The transfer of 
high numbers of Treg cells may lead to a global immunosuppression. Despite this 
concern, patients infused with Treg cells were not reported to be more susceptible to 
infection (139). Secondly, the heterogeneity of the human FoxP3+ population and the 
absence of exclusive marker for human Treg cells make their discrimination from other T 
cells difficult. Indeed, human Treg cells are so far identified as CD25high and CD127low, a 
phenotype shared by activated T cells. Interestingly, it has been shown (133) that effector 
T cells are particularly sensitive to the anti-proliferative effects of rapamycin. For this 
reason, the addition of rapamycin to Treg cells cultured under expanding conditions 
selectively increases the purity of Treg cells.  
However, these therapies were mainly described in GVHD and hematopoietic stem cells 
transplantation (HSCT) patients and whether or not they can also be used for solid organ 
transplantation remains to be determined.  
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1.4.6 Skin transplantation  
Skin transplantation is used in a variety of clinical situations, including skin reconstitution 
after major burn injuries (140). However, skin grafts are rejected in an acute fashion and 
immunosuppressive agents known to be effective in preventing organ transplant 
rejection, have little or no effect on skin transplantation. For these reasons, clinical skin 
transplantation is currently confined to autografts (141). It is therefore of primary 
importance to study the rejection process in mouse models in order to understand and 
target new mechanisms for the establishment of skin transplantation tolerance.  
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2 Material and Methods 
2.1 Mice  
Wild-type inbred C57BL/6/J, Rag2-/-/J, B6.129S7-IFN-gr1tm1Agt/J (Jackson Laboratory), 
IFN-γ-/- (142), CD3-/- (143), B6.C-H-2Bm12 (144), TCR transgenic ABM Rag2-/- mice 
reactive to MHCII I-Abm12 (145), FOXP3eGFP (146), and Bm12 Rag2-/- as well as Bm12 
Ly5.1 (generated in this study) were bred in the Animal House of the Department of 
Biomedicine, University Hospital Basel and Füllingsdorf, Switzerland according to the 
regulations of Swiss veterinary law.  
2.2 Antibodies and reagents  
Monoclonal antibodies recognizing TCR Vα2 (B20.1), TCR Vβ8.1, 8.2 (KJ16-133.18), CD3 
(145-2C11), CD4 (GK1.5), CD11c (N418), CD16/32 (93), CD25 (PC61), CD31 (390), CD40 
(3/23), CD44 (IM7), CD45.2 (104), CD62L (MEL-14), CD69 (H1.2F3), CD80 (16-10A1), 
CD86 (GL-1), CD140a (APA5), CD197 (4B12), CD274 (10F.9G2), CD279 (RMP1-30), 
podoplanin (gp38, 8.1.1), IFN-γ (XMG1.2), FOXP3 (150D), MHC-II (AF6-120.1, 25-9-17), 
fluorochrome-labeled streptavidins, and the fixation and permeabilization kit with BD 
GolgiStop were purchased from Biolegend and BD Pharmingen. Specificity of staining 
was confirmed with isotype-matched control antibodies. The proliferation dye eFluor670 
was purchased from eBioscience. Recombinant IL-7, GM-CSF and IFN-γ (Prepro Tech). 
IL-7 complex was formed by incubation of recombinant mouse IL-7 and M25-Ab (kindly 
provided by Daniela Finke, DBM, Basel) to stimulate IL-7R signaling on various cell types. 
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Sandwich ELISAs were purchased from BD Biosciences and R&D Systems. Phorbol 12-
myristate 13-acetate and ionomycin were purchased from Sigma, Collagenase IV from 
Worthington, DNaseI and Collagenase D from Roche.  
2.3 Preparation of lymph node cells 
Naïve transgenic Vα2Vβ8 CD4+ T cells were isolated from lymph nodes of ABM mice. 
Treg cells were sorted from FOXP3eGFP mice. Lymph node stromal cell were isolated 
according to the protocol adapted from Link et al., 2007 (97). Briefly lymph nodes were 
opened with needles and first digested in DMEM (1.2 mM CaCl2, 2% FCS, Pen/StreP) 
containing collagenase IV (1mg/ml) and DNase1 (40 mg/ml) to isolate lymphocytes. In a 
second digestion step with DMEM containing collagenase D (1mg/ml) and DNase1 (40 
mg/ml), stromal lymph node cells were isolated and used for experiments or further 
sorted to isolate subpopulations.  
2.4 Sorting 
GFP positive Treg cells were sorted with a 70-μm tip at a pressure of 60 psi. Dendritic 
cells and lymph node stromal cells were sorted by CD45, CD11c, gp38 and CD31 
staining with a 100-µm tip at a pressure of 30psi. The purity of sorted cells routinely 
exceeded 98% with an Influx cell sorter (BD). 
2.5 Flow cytometry 
Cell suspensions were stained in ice-cold HBSS supplemented with 2% (vol/vol) FCS for 
surface staining. For intracellular cytokine staining, cells were stained for surface markers, 
were fixed and then resuspended in permeabilization buffer (BD) containing anti-IFN-γ, 
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anti-FoxP3eGFP. Data were acquired on a FACS Canto II (BD Biosciences) and analyzed 
with FlowJo software (TreeStar). If required, PI staining to exclude dead cells was 
performed directly before flow cytometry analysis. 
2.6 Skin transplantation model 
Donor mice were transplanted on the back with full-thickness tail-skin from allogeneic 
Bm12, or syngeneic mice under general anesthesia with Isofluorane. A piece of ca. 1cm2 
of back skin of the recipient mouse was removed and substituted with a piece of tail skin 
of the same size from the donor. Grafts were glued using Histoacryl® (Aesculap AG, 
Tuttlingen, Germany) and covered with Vaseline lubricated finger strips (Hansaplast, 
Beiersdorf, Germany). After 7 days, bandages were removed and mice were kept for an 
additional 14 days to allow wound healing. After complete wound healing, naïve ABM and 
Treg cells were adoptively transferred (i.v.) into recipient mice at different ratios. Graft 
appearance was assessed until rejection and for a maximum of 100 days using the 
following scoring system: 3, short hair, black stripe, shiny greyish appearance; 2, small 
red area, loss of hair shine and dryness; 1, large red area, no black stripe and dryness; 
and 0, rejected. At indicated time points, lymph nodes and skin grafts were collected and 
cells were isolated.  
2.7 RT-PCR from cells 
mRNA was isolated from either single cell suspension of T cells, DCs and stromal cells or 
total lymph node cells by µMACS™ mRNA Isolation Kit. Reverse transcription was carried 
out using One-step cDNA Kit from Miltenyi Biotech according to the manufacturer’s 
protocol. Amplification was performed in 10µl with GoTaq qPCR Master Mix (Promega) 
Material and Methods 
 
 
40 
using Real-Time PCR (Applied Biosystems 7900HT). The following program was used: 40 
cycles of 50°C for 2 min, 95°C for 2 min, 95°C for 15 s, 60°C for 1 min. Primers for RT-
PCR were designed using Universal ProbeLibrary Assay Design Center from Roche 
Applied Biosystems and synthesized by Microsynth (Balgach, Switzerland) and are listed 
in Supplements.  
2.8 Generation of bone-marrow derived DCs 
DCs were generated as described (147). Briefly, bone marrow cells from tibia and femur 
were flushed with RPMI medium. CD11b+ BMDCs (DCs) were generated by plating bone 
marrow progenitors in complete RPMI 1640 (with Pen/Strep, 2-mercaptoethanol (all from 
Invitrogen), 10% (vol/vol) heat-inactivated FBS (BioConcept) and supplemented with 10% 
conditioned medium from GM-CSF transduced X63 (148). After 3 days, non-adherent 
cells were removed and attached cells were further cultured in supplemented RPMI 
medium. On day 5 to 8, cells were harvested and analyzed for CD11c+ expression which 
was routinely 80-90% positive. 
2.9 Expansion of FRC like stromal cells ex vivo 
After digestion, stromal cells were plated in six-well plates at a density of 20 x 106 cells 
per well in complete RPMI medium. After 24h and 48h, non-adherent cells were removed 
and adherent cells were further incubated for 5 days. Adherent cells were detached with 
0.05% Trypsin (GIBCO) and stromal cells were isolated by CD45 depletion (Miltenyi 
Biotech). Purified stromal cells were 12% CD31+ and 84% gp38+ and contained less 
than 2% CD45+ cells. 
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2.10   Stimulation of stromal and dendritic cells 
For analysis of cytokine production and surface marker expression, 5x104 LNSCs 
with/without 2x105 DC per well were cultured in 96 well plates in 200 µl RPMI 1640 
containing the indicated cytokines. Surface expression of selected proteins was analyzed 
by flow cytometry and cytokines were quantified by sandwich ELISA according to the 
manufacturer’s instructions (BD Biosciences). 
2.11   In vitro T cell stimulation assay 
5 x 103 LN cells were seeded in 96-well plates for 4h. EFluor670 stained ABM cells (5 x 
103/well) and different ratio of Treg cells (5 x 103/well to 5 x 104/well) were incubated in 
RPMI medium containing 8U/ml hrIL-2 and 2 x 104 CD3/CD28 dynabeads (Invitrogen). In 
some experiments recombinant cytokines or cytokines antibody complexes were added. 
At indicated time points supernatants were collected to determine cytokine release and 
cells were analyzed for mRNA expression, proliferation, and surface markers expression 
by flow cytometry.  
2.12   MACS separation 
Cells were separated using positive and negative cell isolation kits (Miltenyi) for isolation 
of CD11c+ DCs and CD45- stromal cells with AutoMACS according to manufacturer’s 
instructions. 
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2.13   Assessment of protein expression  
Total proteins were extracted in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 
1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS, and phosphatase/protease inhibitors 
(Roche). Protein concentration was determined using BCA protein assay kit (Pierce 
Biotechnology). Five µg of proteins were resolved on 10% SDS-PAGE and transferred on 
PVDF membranes. After 2h blocking in 5% milk TBST (TBS, 0.2% Tween 20), the 
membranes were incubated with primary antibodies diluted in 1% milk TBST (over night, 
4°C) followed by washing steps and incubation with horseradish peroxidase - conjugated 
secondary antibody (2h, room temperature). Proteins were visualized using ECL Luminata 
Forte/Crescendo Western HRP Substrate (Millipore) and exposed to X-ray film (Fuji 
Medical X-Ray Film). Revelation was performed in an Agfa Processor and bands 
densitometry was analyzed with ImageJ Software 
2.14   Statistical analysis  
Statistical analyses were performed using Prism (GraphPad Software, Inc.). Data for 
expression of mRNA, cytokines and surface protein expression were analyzed using the 
one-way ANOVA with Bonferroni’s multiple comparison test or the Mann-Whitney t test or 
unpaired two tailed student’s t test. Graft survival was analyzed using the Kaplan-Meier 
Log-rank (Mantel Cox) test. P values < 0.05 are considered as statistically different. 
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2.15   Primer List   
Primer Name Sequence (5' -> 3') Primer size Amplicon size 
β-actin f ACG TAG CCA TCC AGG CTG TG 20  124 
β-actin r TGG CGT GAG GGA GAG CAT 18   
CCL19 f TGT GGC CTG CCT CAG ATT AT 20 122 
CCL19 r AGT CGG CCG CAT CAT TAG CAC 21   
CCL21 f TCC AAG GGC TGC AAG AGA 18 92 
CCL21 r TGA AGT TCG TGG GGG ATC T 19   
IAb f GTG GTG CTG ATG GTG CTG 18 76 
IAb r CCA TGA ACT GGT ACA CGA AAT G 22   
ICAM-1 f CCC ACG CTA CCT CTG CTC 18 72 
ICAM-1 r GAT GGA TAC CTG AGC ATC ACC 21  
IFN-γR1 f TCA AAA GAG TTC CTT ATG TGC CTA 24 93 
IFN-γR1 r TAC GAG GAC GGA GAG CTG TT 20  
IL-2R f TGT GCT CAC AAT GGA GTA TAA GG 23 72 
IL-2R r CTC AGG AGG AGG ATG CTG AT 20   
IL-7 f AAA GCC AGA GCG CCT GGG TG 20 108 
IL-7 r CTG GGC AGG GCA GTT CAG GC 20   
Nos2 f GGG CTG TCA CGG AGA TCA 18 66 
Nos2 r CCA TGA TGG TCA CAT TCT GC 20  
Nos3 f CCA GTG CCC TGC TTC ATC 18 66 
Nos3 r GCAGGGCAAGTTAGGATCAG 20  
PD-1 f TGC AGT TGA GCT GGC AAT 18 77 
PD-1 r GGC TGG GTA GAA GGT GAG G 19   
PD-L1 f CCA TCC TGT TGT TCC TCA TTG 21 76 
PD-L1 r TCC ACA TCT AGC ATT CTC ACT TG 23   
TSLP f GGA CTG TGA GAG CAA GCC AGC TT 23 91 
TSLP r TGT TTT GTC GGG GAG TGA AGG GC 23   
VCAM-1 f TGG TGA AAT GGA ATC TGA ACC 21 86 
VCAM-1 r CCC AGA TGG TGG TTT CCT T 19  
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3 Aim of thesis 
Treg cells are known to play an important role in suppressing immune responses, and 
have been demonstrated to be important for establishing allograft tolerance. Suppression 
of immune responses can be either established in the allograft or in the LNs. The LN is 
composed of stromal cells that form a conduit system and provide a structural 
environment for homeostasis and differentiation of lymphocytes. Moreover, LNSCs were 
shown to provide survival factors and negatively regulate activated T cells during strong 
inflammatory responses. However, the role of LNSCs during alloresponses and Treg-
mediated tolerance is still unknown. 
The aim of my doctoral thesis was to establish a skin transplantation model in which the 
transfer of polyclonal Treg cells suppresses anti-bm12 specific effector CD4 T cells 
capable of mediating graft rejection and to characterize the microenvironment of the LN 
at different time points. Of particular interest was the interaction of Treg cells and TRCs 
during establishment and maintenance of skin allograft tolerance in mice.  
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4 Results 
4.1 Establishment of skin transplantation model in Rag2-/- mice 
To study the role of Treg-mediated tolerance and its consequences for the LN 
microenvironment, we chose the bm12 skin transplantation model. A spontaneous three 
point mutation in the antigen presenting groove of the IAb molecule (IAbm12) was shown to 
elicit an alloimmune response and graft rejection in C57BL/6 mice (144). Consistent with 
published data (144), C57BL/6 WT recipient mice rejected the graft within 14 days (Fig. 1). 
To confirm the dependence of graft rejection on T cells, T-cells deficient CD3e-/- and T- 
and B-cells deficient Rag2-/- mice were also transplanted. Both, CD3e-/- and Rag2-/- mice 
showed prolonged graft survival up to 100 days (Fig. 1).  
 
 
Figure 1. CD3e-/- and Rag2-/- mice are tolerant for the Bm12 skin graft. C57BL/6 WT 
(black, n = 21), CD3e-/- (gray, n = 6) or Rag2-/- (white, n = 15) recipient mice received bm12 
skin allografts on day 0. Graft survival is displayed as Kaplan-Meier plot. The difference 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
B6
CD3e-/-
Rag2-/- 
Days after transplantation
G
ra
ft 
su
rv
iv
al
 (%
)
Results 
 
 
48 
between C57BL/6 and the other recipient groups is statistically significant (p < 0.0001) using 
Log-rank (Mantel Cox) test.  
However, adoptive transfer of Treg cells into bm12-transplanted C57BL/6 mice did not 
prevent skin graft rejection and depletion of C57BL/6 mice with anti-CD3 was not 
sufficient to induce graft tolerance (personal communication, Simona Rossi).  
Bill et al. identified that monoclonal anti-bm12 (ABM) specific CD4+ effector T cells 
express the Vα2Vβ8 TCR and acquire effector functions after encounter with the cognate 
antigen (149). Adoptive transfer of 2 x 104 transgenic ABM cells in Rag2-/- mice induced 
graft rejection within 12 days, which was delayed by adoptive transfer of polyclonal Treg 
cells (Fig. 2). Co-injection of 2-fold more Treg cells prolonged graft survival up to 16 days 
and injection of 10-fold more Treg cells (2 x 105) induced graft tolerance up to 100 days 
(Fig. 2).  
 
 
Figure 2. Treg cells induce prolonged Bm12 skin graft survival. Allograft transplanted 
Rag2-/- mice (n ≥ 7) were adoptively transferred with ABM cells (black) or Treg cells (blue) 
alone or in combination at different Treg : ABM ratios (yellow, orange, red) on day 0. Graft 
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survival is displayed as Kaplan-Meier plot. The difference between the groups is statistically 
significant (p < 0.0001) using Log-rank (Mantel Cox) test.  
4.2 Migration and homing of ABM and Treg cells to skin grafts 
and LNs 
To elicit an immune response, T cells have to encounter DCs in the LN displaying the 
cognate antigen. Treg mediated suppression in the LN might change the recruitment and 
maturation of DCs. To address this possibility, we analyzed host DCs (Fig. 3, circles) 
residing in the LNs of transplanted mice 6 days after T cell adoptive transfer. DC number 
and frequency as well as activation marker expression including MHC class II (IAb), CD40, 
CD80 and CD86 were similar in the ABM, 2:1 and 10:1 group (Fig. 3, B).  
Next we investigated the migration of DCs from donor Ly5.1 bm12 grafts on day 0 (data 
not shown) and day 6 after adoptive T cell transfer (Fig. 3, squares). Donor DCs were 
detectable in similar numbers and frequencies in the draining LN of transplanted mice. 
Their expression of MHC class II and co-stimulatory molecules CD40, CD80 and CD86 
was higher compared to the expression on host DCs, albeit not different in the ABM, 2:1 
and 10:1 group (Fig. 3, B). These results suggest that the presence of Treg cells does not 
impair the migration and activation of skin graft-derived donor DCs.  
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Figure 3. Treg cells do not affect numbers and phenotype of host and donor DCs in 
LNs. (A) Ly5.1−	
 CD11c+ host DCs (circles) and Ly5.1+	
 CD11c+ donor DCs (squares) numbers 
(left) and frequencies (right) and (B) their phenotype was determined using flow cytometry for 
IAb, CD40, CD80 and CD86. ABM alone (black), and the Treg:ABM ratios 2:1 (yellow) and 
10:1 (red) group 6 after adoptive T cell transfer. n ≥ 3. Data are representative of one 
experiment out of two. Differences between the groups were not significant using the Mann 
Whitney t test. Error bars denote interquartile range.  
Next we investigated the recruitment of ABM and Treg cells to the skin graft and their 
expression of the skin homing receptor, CCR4, and the activation marker CD25. 
Recruitment of both T cell subsets was similar in all groups until day 9 (Fig. 4, A). The 
expression of CCR4 on ABM cells transferred at a 2:1 ratio with Treg cells was higher 
compared with ABM cell transferred alone, while in the 10:1 group ABM express CCR4 in 
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a comparable manner to the ABM group. However the different expression of CCR4 did 
not correlate with higher ABM counts in the skin graft of the 2:1 group. Treg cells had 
similar levels of CCR4 expression in the 2:1, 10:1 and Treg group. The expression of 
CD25 on ABM cells was comparable in all groups, while Treg cells expressed higher 
levels of CD25 in the 10:1 group compared to Treg transferred alone (Fig. 4, B).  
 
Figure 4. Migration and phenotype of ABM and Treg cells following Bm12 skin graft 
transplantation. (A) ABM cells (left) were detected via Vα2Vβ8 TCR staining and Treg cells 
(right) via FoxP3eGFP expression in the skin graft in the ABM (black), 2:1 (yellow), 5:1 
(orange), 10:1 (red) and Treg (blue) group by flow cytometry on day 3, 6 and 9 after adoptive 
T cells transfer. Cell number per skin graft is plotted over the time after adoptive T cells 
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transfer. Error bars denote SEM. n ≥ 4. (B) Surface expression of CCR4 and CD25 on ABM 
cells (left) and Treg cells (right) was determined by flow cytometry on day 9. Statistical 
analysis was performed using the Mann Whitney t test by comparing to the ABM or Treg 
group. *, P < 0.05. Error bars denote interquartile range. n = 4. 
The presence of Treg cells in the 2:1 and 10:1 group might create a tolerogeneic milieu in 
the skin graft within 9 days. To test this we transplanted C57BL/6 mice with skin grafts 
removed from mice transferred with 2:1 and 10:1 Treg:ABM cell ratios and compared 
them with grafts removed from mice receiving ABM cells alone. All grafts were rejected by 
day 35, suggesting that Treg cells establish tolerance in the LN and not in the graft (Fig. 
5).  
 
Figure 5. Treg cells do not establish tolerance in skin grafts. C57BL/6 WT recipients 
were transplanted with Bm12 allografts removed from the different group (ABM (black, n = 
3), 2:1 (yellow, n = 3) and 10:1 (red, n = 2)) of Rag2-/- transplanted mice 9 days after adoptive 
T cells transfer. Graft survival is displayed as Kaplan-Meier plot. The difference between the 
groups is not statistically significant. 
All groups showed comparable migration of ABM cells to a pool of axillary, brachial and 
inguinal LNs on days 6 and 9 (Fig. 6, A). On day 9, the number of ABM cells was higher in 
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the absence of Treg cells and significantly lower in the 2:1, 5:1 and 10:1 group (Fig. 6, A 
and B). However, Treg cells were present in comparable numbers in the LNs on day 6 and 
9 (Fig. 6, A and B). Interestingly, by calculating the ratio of Treg cell to ABM cell numbers 
at 9 days after adoptive transfer, we found that a ratio >1 correlates with long term 
tolerance of the skin graft (Fig. 6, C). Taken together, our data indicate that ABM 
mediated skin graft rejection can be suppressed by double amount of Treg cells in the 
LN. 
 
Figure 6. Treg cells reduce number of ABM cells in the LNs of transplanted mice.             
(A) Counts of Vα2+Vβ8+ ABM cells (left) and FoxP3eGFP+ Treg cells (right) were quantified in 
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the LNs in the ABM (black), 2:1 (yellow), 5:1 (orange) and 10:1 (red) group by flow cytometry 
on day 3, 6 and 9 after adoptive T cells transfer. (B) Counts of ABM (left) and Treg cells 
(right) on day 9 were compared with 2:1, 5:1 and 10:1 groups using the Mann-Whitney t test. 
**, P < 0.01; ***, P < 0.001. Error bars denote SEM. (C) Treg : ABM cells ratio in the 2:1, 5:1 
and 10:1 group in the LN on day 9. The dotted line represents the threshold (ratio = 1). 
Statistical analysis was performed using a One-way analysis of variance with Bonferroni’s 
Multiple Comparison test (significant for P value < 0.05). n ≥ 4. Error bars denote SEM. 
4.3 Bm12 mediated ABM and Treg cells expansion in LNs 
Under lymphopenic conditions, both homeostatic proliferation and survival modulate T 
cell expansion in the LNs. To understand the relative contributions of homeostatic 
proliferation and Ag-driven proliferation, we compared allografts and syngrafts from Rag2-
/- mice on day 9. In allografted mice, decreased numbers of ABM cells were recovered in 
the presence of transferred Treg cells (Fig. 6, B). In syngrafted mice, ABM cell numbers 
were independent of the number of Treg cells (Fig. 7, A, left), indicating that Treg cells 
suppress only Ag-driven proliferation of ABM cells. Next we analyzed the percentages of 
recovered ABM cells in the LNs with the formula (no. ABMday 9 / no. ABMday 0)*100. In LNs 
of allotransplanted mice, ~94%, ~25% and ~7% of injected ABM were recovered in the 
ABM, 2:1, and 10:1 group respectively. In syngrafted mice, only 1% of ABM cells were 
recovered in all groups (Fig. 7, A, right).  
In allografted mice, Treg cell numbers were similar in all groups (Fig. 6, B) and in 
syngrafted mice Treg cell numbers were higher in the 10:1 and Treg group (Fig. 7, B, left). 
Interestingly, in allografted mice ~7% of Treg cells were recovered in 2:1 group, ~2% in 
the 10:1 group and ~1% in the Treg group. In syngrafted mice only ~1% of Treg cells 
were detected in the LNs in all groups (Fig. 7, B, right). These data suggest that ~1% of 
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naïve ABM and Treg cells survive in the LNs and that bm12-activation of ABM cells might 
lead to expansion of both ABM and Treg cells.  
 
Figure 7. Bm12-specific ABM and Treg cells expansion in LNs. (A) Counts of Vα2+Vβ8+ 
ABM cells in the LNs of syngrafted mice (left). Percentage of recovered ABM cells ((no. 
ABMday 9 / no. ABMday 0)*100) (right) in allograft and syngraft of transplanted mice in the 
different groups. (B) Counts of Foxp3eGFP Treg cells in the syngrafted mice (left). 
Percentage of recovered Treg cells (right) in allograft and syngraft of transplanted mice in 
the different groups. Statistical analysis was performed using the Mann Whitney t test by 
comparing to the control (ABM or Treg) group. *, P < 0.05; **, P < 0.01, ***, P < 0.001. Error 
bars denote SEM. n = 7  
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4.4 Phenotypical analysis of ABM cells in the presence of Treg 
cells 
We next analyzed the activation status of ABM cells in the skin draining LNs of 
transplanted mice 6 (data not shown) and 9 days (Fig. 8, A) after adoptive transfer of T 
cells (ABM, 2:1, 10:1 groups).  
Six and nine days after adoptive transfer, the surface expression of the LN-homing 
chemokine receptor CCR7 was similar in all groups. CD62L and IL-7R were 
downregulated after adoptive transfer (data not shown), but this downregulation was 
independent of the presence of Treg cells. The early activation marker CD69 was 
expressed more highly in the 10:1 group than in the ABM group on day 9. CD44 and 
CD25 as well as the inhibitory TIM-3 and PD-1 molecules were comparable in all groups 
(Fig. 8). With the exception of CD44 and the upregulation of CD69 in the 10:1 group, 
expression of these surface markers was similar in syngrafted mice (data not shown), 
suggesting that the activation of ABM cells is induced by homeostatic proliferation and is 
not inhibited by Treg cells.  
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Figure 8. Treg cells do not inhibit ABM cells activation in the LNs. Surface expression 
(mean fluorescence intensity, MFI) of CCR7, CD62L, IL-7R, CD69, CD44, CD25, TIM-3 and 
PD-1 on ABM cells in the ABM (black), 2:1 (yellow) and 10:1 (red) groups on day 9 was 
determined by FACS analysis. Statistical analysis was performed using the Mann Whitney t 
test by comparing to the ABM group. **, P < 0.01. Data pooled from two independent 
experiments. Error bars denote SEM. n = 7 
To study the effect of Treg cells on ABM cell activity we analyzed ABM T cell proliferation 
and cytokine production both in vitro and in vivo. In vitro, high numbers of Treg cells 
suppressed the proliferation of ABM cells as determined by the dilution of the eFluor670 
dye (Fig. 9, A). Moreover, IFN-γ and IL-2 production by bm12-DC activated ABM cells 
were decreased in the presence of high numbers of Treg cells (Fig. 9, B). In agreement 
with these in vitro data, transferred Treg cells inhibit ABM cell proliferation in a cell 
number dependent manner on day 9 (Fig. 9, C) and reduced the numbers of IFN-γ+ Vα2+ 
Vβ8+ ABM cells isolated from LNs of the 10:1 group (Fig. 9, D,E). Taken together, our data 
indicate that Treg cells inhibit the expansion of LN homing ABM cells and impair their 
production of effector cytokines.  
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Figure 9. Treg cells delay proliferation and impair cytokine production of ABM cells. (A) 
Representative plot of the in vitro proliferation of ABM cells stimulated with anti-CD3/CD28 
beads for 5 days determined by eFluor670 proliferation dye staining in the 10:1 (red) and 
ABM (black) group. The grey curve represents the fluorescence of undivided cells on day 0. 
(B) IFN-γ and IL-2 cytokines production measured by ELISA in the supernatant of ABM cells 
cocultured with Bm12 Rag2-/- LN cells in the absence (ABM, black) or presence (10:1, red) of 
Treg cells for 72h. Cytokine secretion by Treg alone is represented in blue. The dotted line 
represents the cytokine detection background. Data are representative of three independent 
experiments. Error bars denote SEM. (C) Representative plot of the proliferation of ABM 
cells determined by eFluor670 proliferation dye staining in the different groups on day 9. The 
grey curve represents the fluorescence of undivided cells on day 0. Data are representative 
of three independent experiments. (D) Representative plot of the in vivo IFN-γ production of 
ABM cells isolated from the LNs of the ABM (left) and 10:1 (right) group which were 
restimulated in vitro with PMA/ionomycin (4h) and were stained for intracellular IFN-γ. (E) 
Percentage of IFN-γ producing ABM cells in the different groups. n = 4. Statistical analysis 
was performed using the Mann Whitney t test by comparing to the ABM group. *, P < 0.05; 
**, P < 0.01. Error bars denote SEM. 
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4.5 Effect of adaptive immune cells on LNSCs  
In recent years it has become clear that hematopoietic cells, including Treg cells, are not 
the sole regulators of T cell tolerance and immune responses. Indeed, non-hematopoietic 
LNSCs have been shown to modulate T cells responses in the LNs (105). To address a 
role of LNSCs in our model we first examined how T cells affect LNSCs under steady-
state conditions. LNSC populations from C57BL/6, CD3e-/- and Rag2-/- mice were 
analyzed for markers to identify TRC (gp38+CD31-), LEC (gp38+CD31+), BEC (gp38-CD31+) 
and DNC (gp38-CD31-) (Fig. 10, A) subsets. The absence of T cells did not affect the 
numbers or frequencies of LNSC populations (Fig. 10, B).  
 
Figure 10. C57BL/6, CD3e-/- and Rag2-/- mice have similar LNSC distribution.                 
(A) Representative plot of LNSC subpopulations identified in C57BL/6, CD3e-/- and Rag2-/- 
mice by flow cytometry analysis. CD45− cells were stained for gp38 and CD31 that define 
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TRC (gp38+CD31-), LEC (gp38+CD31+), BEC (gp38-CD31+) and DNCs (gp38-CD31-). (B) 
Counts (left) and frequencies (right) of TRC, LEC, BEC, and DNC in the LNs of C57BL/6 
(black), CD3e-/- (gray), Rag2-/- (white). Error bars denote SEM. n = 3. Data are representative 
of three independent experiments. 
We next addressed the transcriptional profile of the TRC subset since they are the main 
LNSC population to come into contact with T cells. TRCs attract naïve T cells to the LNs 
via the release of CCL19 and CCL21 and might interact with them via ICAM-1 and VCAM-
1 (98). Furthermore, TRCs are the main producer of IL-7 and express PD-L1 and NOS 
upon IFN-γ stimulation. All of these molecules orchestrate effector T cell responses and 
were included in our RT-PCR analysis. Gene transcription of the selected genes was not 
affected by the absence of T or B cells under non-inflammatory conditions (Fig. 11). 
In agreement with this analysis, ICAM-1 and PD-L1 surface expression was similar in all 
cases. In contrast, MHC class II (IAb) surface expression was dependent on the presence 
of T cells (Fig. 11), probably due to the absence of T cells that have been shown to 
require MHC class II molecules during T cell homeostasis (150, 151).  
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Figure 11. IAb expression on TRCs is dependent on the presence of T cells.                       
(A) Quantitative RT-PCR analysis of relative mRNA expression for different genes from 
CD45−gp38+CD31− sorted TRCs from C57BL/6 (black), CD3e-/- (light gray), Rag2-/- (white). n = 
5 (B) Cell surface expression (MFI) of ICAM-1, PD-L1 and IAb on TRC isolated from the 
different mice and analyzed by flow cytometry. Statistical analysis was performed using the 
Mann Whitney t test by comparing to the C57BL/6 group. *, P < 0.05; **, P < 0.01. Error bars 
denote SEM. n = 3.  
4.6 IFN-γ modulates the biological activity of TRCs in vitro  
IFN-γ and tumor necrosis factor (TNF) secreted by CD8 T cells plays a role in modulating 
TRC mediated suppression of T cell proliferation (104, 120). To understand the effect of 
IFN-γ on TRC phenotype, in vitro expanded TRCs were stimulated with IFN-γ. Culture 
with IFN-γ resulted in the up-regulation of the adhesion molecules ICAM-1 and VCAM-1, 
IAb, NOS2, NOS3 and PD-L1. In contrast, IL-7, TSLP and IFN-γ-R were not altered upon 
IFN-γ stimulation (Fig. 12, A). In line with the transcription analysis, IFN-γ stimulation led 
to the up-regulation of surface expression of IAb, PD-L1 and ICAM-1 but not VCAM-1. In 
order to address the dependency of these changes on TRCs IFN-γ signaling, we analyzed 
the up-regulation of the selected surface markers on TRCs isolated from IFN-γR-/- mice. 
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Following IFN-γ stimulation IFN-γR-/- TRCs failed to up-regulate IAb, PD-L1 and ICAM-1 
(Fig. 12, B).  
 
 
Figure 12. TRCs up-regulate IAb, PD-L1 and ICAM-1 in an IFN-γ dependent manner.                
(A) Quantitative RT-PCR analysis of relative mRNA expression of selected genes from 
unstimulated (white) or IFN-γ stimulated (black) TRCs cell lines 24h after in vitro culture. n ≥ 
9, data pooled from 5 independent experiments. (B) Surface expression (MFI) of IAb, PD-L1, 
ICAM-1 and VCAM-1 on TRCs cell lines derived from C57BL/6 mice (black) or IFN-γR-/- mice 
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stimulated with or without IFN-γ. n = 4. Statistical analysis was performed using an unpaired 
two-tailed student’s t test. Error bars denote SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
4.7 Modulation of TRCs during allo-responses 
To study the modulation of TRCs gene expression and phenotype during acute skin-
transplantation, we isolated TRCs from syngraft-transplanted C57BL/6 mice and 
compared them to allograft-transplanted mice. TRC as well as LEC and BEC numbers 
and frequencies were similar in both syngrafted and allografted mice (Fig. 13, A). TRCs 
isolated from allograft transplanted mice exhibited higher gene transcription of ICAM-1, 
VCAM-1, IAb, IL-7, TSLP and PD-L1 compared with TRCs isolated from syngeneic 
grafted mice (Fig. 13, B). In contrast to these mRNA data, no differences of surface 
marker expression of ICAM-1, VCAM-1, IAb and PD-L1 were observed (Fig. 13, C). We 
cannot exclude that the discrepancy between mRNA and surface protein levels is not a 
consequence of the digestion steps needed to isolate TRCs from LNs which may affect 
the expression of these molecules. 
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Figure 13. Allograft response modifies TRC transcription profile. (A) Counts and 
frequencies of TRCs, LECs and BECs of allograft (black) or syngraft (white) transplanted 
C57BL/6 mice and analyzed by FACS after CD45, CD31 and gp38 staining 7 days after 
transplantation. n = 4. (B) Quantitative RT-PCR analysis of relative mRNA expression for 
different genes from CD45−gp38+CD31− sorted TRCs from Bm12-allograft (n = 6, black) or 
syngraft (n = 7, white) transplanted C57BL/6 mice. The expression of selected genes was 
normalized on β-actin expression. Error bars denote SEM. (C) Surface expression of 
selected molecules was determined by FACS analysis for the different LNSC subsets 7 days 
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after transplantation. Error bars denote interquartile range. n = 4. Statistical analysis was 
performed using the Mann Whitney t test. *, P < 0.05; **, P < 0.01. 
To investigate the role of IFN-γ in the modulation of LNSC activity during alloresponses, 
we transplanted IFN-γ-/- mice with syngraft or Bm12-allograft and analyzed LNSCs 7 days 
after transplantation. The number of TRCs was similar, while LEC and BEC numbers were 
higher during alloresponses. However the LNSC frequencies were similar for all the 
populations. The differences in mRNA expression between TRCs isolated from allogeneic 
and syngeneic transplanted mice were abolished in IFN-γ-/- recipients (Fig. 14).  
Our data underscore the importance of IFN-γ signaling on the transcription profile of 
adhesion and survival molecules in TRCs during acute allogeneic immune responses.  
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Figure 14. Allograft response does not modify TRC transcription profile in the absence 
of IFN-γ. (A) Counts and frequencies of TRCs, LECs and BECs of allograft (black) or 
syngraft (white) transplanted IFN-γ-/- mice and analyzed by FACS after CD45, CD31 and 
gp38 staining 7 days after transplantation. (n = 5) (B) Quantitative RT-PCR analysis of 
relative mRNA expression for different genes from CD45−gp38+CD31− sorted TRCs from 
Bm12-allograft (n = 6, black) or syngraft (n = 6, white) transplanted IFN-γ-/- mice. The 
expression of selected genes was normalized on β-actin expression. (C) Surface expression 
of selected molecules was determined by FACS analysis for the different LNSC subsets 7 
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days after transplantation. n = 5. Statistical analysis was performed using the Mann Whitney 
t test. *, P < 0.05. 
4.8 Modulation of TRCs during Treg-mediated allo-tolerance 
To investigate the response of TRCs during Treg-mediated allo-tolerance, we analyzed 
TRC numbers, transcription profile, and phenotype in Rag2-/- Bm12-transplanted mice. 
TRCs were compared after adoptive transfer of naïve ABM with or without Treg cells on 
day 6 (Fig. 15, A) and day 9 (Fig. 15, B). The transfer of ABM or Treg cells alone or in 
different Treg:ABM ratios (2:1 and 10:1) did not affect the total number or frequency of 
TRCs, or BEC and LEC at either time points (Fig. 15). In addition, the proliferation of 
LNSC subsets was not affected by the presence of Treg cells (2:1 group) in vivo on day 6 
(Fig. 15, C).  
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Figure 15. Co-transfer of Treg cells does not influence number and frequencies TRCs. 
Counts (left) and frequencies (right) of TRCs in the LNs of Bm12-transplanted Rag2-/- mice 
on day 6 (n = 9) (A) and day 9 (n = 6) (B) in ABM (black), 2:1 (yellow), 10:1 (red) and Treg 
(blue) group analyzed by flow cytometry. (C) LNSCs in vivo proliferation was determined by 
bromdesoxyuridin (BrdU) incorporation in the different groups 6 days after adoptive T cells 
transfer. Differences were not significant using the Mann Whitney t test.  
Six days after adoptive T cells transfer, the transcriptional analysis on TRCs showed only 
a few differences in the gene expression profile among the groups. In the 10:1 group IAb 
and PD-L1 were significantly higher compared to the ABM group and baseline expression 
(dotted line) (Fig. 16, A). mRNA levels of chemokines, adhesion molecules, cytokines, 
cytokines receptors and growth factors were not affected by different ratios of Treg cells 
(Fig. 16, A). Surface expression of IAb, PD-L1, ICAM-1 was similar in all groups, whereas 
VCAM-1 was significantly lower expressed on TRCs isolated from the Treg group 
compared to the one isolated from the ABM group (Fig. 16, B).  
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Figure 16. Co-transfer of Treg cells does not influence TRCs activity on day 6. (A) 
Quantitative RT-PCR analysis of relative mRNA expression for different genes from 
CD45−gp38+CD31− sorted TRCs from Bm12-allograft transplanted Rag2-/- mice (n = 4) on 
day 6. The expression of selected genes was normalized on β-actin expression. Dotted line 
represents mRNA levels of TRCs isolated from transplanted not adoptively transferred Rag2-
/- mice. (B) Mean fluorescence intensity of selected markers in the different groups was 
measured by FACS analysis. (n ≥ 6). Statistical analysis was performed using an unpaired 
two-tailed student’s t test. Error bars denote SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
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Nine days after T cell transfer, the expression of ICAM-1, VCAM-1, IAb, PD-L1 and TSLP 
was induced in all groups, while the expression of CCL19 and CCL21, IL-7 and IFN-γR 
was maintained or lower compared to non-injected controls (baseline) (Fig. 17, A). mRNA 
levels of CCL19 and CCL21 were higher after Treg cell transfer in different ratios (2:1, 
10:1, Treg alone) than in the ABM group, suggesting that Treg cells maintain the 
chemokine and cytokine expression of TRCs (Fig. 17, A). The mRNA levels of ICAM-1, 
VCAM-1, IL-7 and TSLP were higher in the 10:1 group and IAb, PD-L1, NOS3 and IFN-γR 
transcripts were comparable in all groups (Fig. 17, A). In contrast to these transcriptional 
data, surface expression of ICAM-1 was similar and VCAM-1 was down regulated in the 
presence of Treg cells (Fig. 16, B). Consistent with the mRNA levels, PD-L1 and IAb 
surface expression was comparable in all groups (Fig. 16, B).  
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Figure 17. Co-transfer of Treg cells modifies transcription profile of TRCs on day 9. (A) 
Quantitative RT-PCR analysis of relative mRNA expression for different genes from 
CD45−gp38+CD31− sorted TRCs from Bm12-allograft transplanted Rag2-/- mice (n = 4) on 
day 9. The expression of selected genes was normalized on β-actin expression. Dotted line 
represents mRNA levels of TRCs isolated from transplanted not adoptively transferred Rag2-
/- mice. (B) Mean fluorescence intensity of selected markers in the different groups was 
measured by FACS analysis. (n ≥ 6). Statistical analysis was performed using an unpaired 
two-tailed student’s t test. Error bars denote SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
Taken together, transcription of the chemoattractans CCL19 and CCL21 is up-regulated 
by Treg cells regardless of the establishment of tolerance, while the transcription of 
adhesion molecules ICAM-1, VCAM-1, IL-7 and TSLP were only up-regulated during 
establishment of Treg mediated tolerance (10:1 group).  
4.9 Activation of Treg cells during tolerance influences their 
function 
To assess whether changes in the transcription profile of TRCs correlates with the 
activation status of Treg cells in the different groups, we analyzed Treg cell phenotype on 
day 6 and day 9 (Fig. 18).  
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72 
On day 6, Treg cells isolated from the 10:1 group were expressing similar surface level of 
CD25, CD44, CD62L, CD69, CCR7, Tim 3, and PD-1 compared to the Treg isolated from 
the Treg only group. We found higher IL-7R expression on Treg cells isolated from the 2:1 
group on day 6 (Fig. 18, A). On day 9, Treg cells from the different groups were similar in 
CD44, CD62L, CD69, IL-7R, and CCR7 expression, whereas suppression of 
alloresponses (10:1 group) increased CD25 and TIM 3 compared to Treg cells from Treg 
only injected mice. Expression of PD-1 was lower in the 2:1 than in the 10:1 and Treg 
group (Fig. 18, B).  
 
Figure 18. Treg cells have higher CD25, TIM-3 and PD-1 during suppression on 
alloresponses. Mean fluorescence intensity of different surface molecules on FoxP3eGFP+ 
Treg cells isolated from the 2:1 (yellow), 10:1 (red) and Treg (blue) group at (A) day 6 (n = 6) 
and (B) day 9 (n ≥ 5). For both time point, pooled data of two independent experiments. 
Statistical analysis was performed using the Mann Whitney t test. *, P < 0.05; **, P < 0.01. 
Error bars denote interquartile range.  
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4.10   Effect of IL-7 on Treg cells 
Given our observation that IL-7 transcription in TRCs was higher during Treg-mediated 
skin graft tolerance compared to the ABM group (Fig. 17, A), we next analyzed the 
molecular basis of IL-7R signaling on Treg cells in vitro. In agreement with previous 
reports (86-88), we confirmed constitutive expression of IL-7R on Treg cells and IL-7R 
down regulation following treatment with IL-7 (Fig. 19, A). In addition, IL-7 induced STAT5 
phosphorylation (Fig. 19, B) and increased survival of naïve Treg cells in vitro (Fig. 19, C). 
Moreover, Treg cells had higher surface CD25 expression in the presence of IL-7, while 
CD62L, CD69, PD-1 and TIM-3 surface expression were similar (Fig. 19, D).  
 
Figure 19. IL-7R signaling on Treg cells enhances survival and CD25 expression.             
(A) Representative plot of IL-7R and CD25 expression (left) and mean fluorescence intensity 
of IL-7R (right) on unstimulated (black) or IL-7-stimulated (red) naïve Treg cells analyzed by 
flow cytometry after 24h of in vitro culture. n ≥ 18 pooled data from 4 different experiments. 
(B) Ratio of phosphorylated STAT5 on STAT5 after 0, 10 and 30 minutes IL-7 stimulation. (C) 
Cells counts and phenotype (D) of unstimulated (black) or IL-7-stimulated (red) naïve Treg 
cells analyzed by flow cytometry after 24h of in vitro culture. n ≥ 18 pooled data from 4 
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different experiments. Statistical analysis was performed using an unpaired two-tailed 
student’s t test. Error bars denote interquartile range. **, P < 0.01; ***, P < 0.001.  
To investigate the effect of IL-7 during activation, we stimulated Treg cells with 
CD3/CD28 Ab-coated beads for 4 days. Activated Treg cells were present in higher 
numbers after IL-7 stimulation (Fig. 20, A) and responded in a similar fashion by 
downregulating IL-7R and increasing CD25 expression (Fig. 20, B). By comparing IL-7 
with IL-2 stimulated Treg cells, we found that IL-2 strongly increased Treg numbers (Fig. 
20, A) and CD25 expression, which was not further enhanced by the addition of IL-7 (Fig. 
20, B). Moreover, TIM-3 expression was upregulated on activated Treg cells by IL-2, while 
PD-1 expression was unaltered by the cytokine stimulations. 
 
Figure 20. Activated Treg cells can sense IL-7. (A) Cell counts and phenotype (B) of 
unstimulated (black) or IL-7- (red), IL-2- (light blue) and IL-2/IL-7 (blue)-stimulated anti-
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CD3/CD28 activated Treg cells analyzed by flow cytometry after 4 days of in vitro culture. n 
≥ 11 pooled data from 4 different experiments. Statistical analysis was performed using an 
unpaired two-tailed student’s t test. Error bars denote interquartile range. *, P < 0.05; **, P < 
0.01; ***, P < 0.001.  
The CD25 molecule is constitutively expressed on the surface of Treg cells and 
contributes to Treg mediated suppression by sequestering IL-2 produced by ABM 
effector cells. To examine the effect of IL-7 on Treg activity, we studied the ability of Treg 
cells to suppress ABM cells proliferation following IL-7 stimulation in vitro. In the absence 
of Treg cells, the MFI of the proliferation-dye on ABM cells was higher by the addition of 
exogenous IL-7, suggesting that ABM cells alone are less proliferating in the presence of 
IL-7. Treg cells, in a 2:1 situation, were increasing the MFI of ABM cells which was higher 
by the addition of exogenous IL-7 in vitro (Figure 21), suggesting that IL-7-mediated 
CD25 upregulation on Treg cells enhance their ability to suppress proliferation.  
 
Figure 21. IL-7 stimulation enhances Treg-mediated suppression of ABM cells.           
(A) Proliferation of eFluor670 stained ABM cells measured after 5 days of anti-CD3/CD28 
beads activation in vitro without hrIL-2. ABM cells were cultured alone (black) or together 
with Treg cells in a 2:1 situation (red) without any additional stimulation or with 50ng/ml IL-7 
(ABM, blue and 2:1, green). (B) Proliferation presented as MFI of proliferation dye eFluor670. 
Data are represented as median with interquartile range. n = 4. Statistical analysis was 
performed using an unpaired two-tailed student’s t test. **, P < 0.01; ***, P < 0.001. 
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4.11   Interaction of Treg cells and TRCs in vitro 
Finally, we investigated whether exposure to IL-7 in addition to the contact with TRCs 
modulate naïve (Fig. 22, circles) and activated (Fig. 22, squares) Treg cells. Since TRC cell 
lines have been shown to express only low levels of IL-7 (104), we added exogenous IL-7 
to the culture. Furthermore, to mimic the 10:1 situation in vivo, we added IFN-γ and IL-7 
to the Treg in vitro. The IL-7-mediated increase in naïve and activated Treg cell counts 
(Fig. 22) was abolished in the presence of TRCs and was not further changed in the 
presence of IFN-γ (Fig. 22, A). IL-7R downregulation and the CD25 up-regulation on naïve 
but not on activated Treg cells were maintained in the presence of TRCs (Fig. 22, B). 
CD62L was downregulated on naïve Treg cells after IFN-γ + IL-7 stimulation, while CD69 
and TIM-3 were not differently expressed by the different cytokine stimuli. Beads 
activated Treg cells showed CD62L downregulation, and upregulation of CD69, CD25 and 
TIM-3, independent of cytokine stimulation.  
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Figure 22. Effect of IL-7 on Treg cells in the presence of TRCs. (A) Cell counts and 
phenotype (B) of naïve (circles) or anti-CD3/CD28 activated (quares) Treg cells unstimulated 
(black) or IL-7- (red), IFN-γ/IL-7 (yellow)-stimulated analyzed by flow cytometry after 4 days 
of in vitro coculture with TRC cell line. n ≥ 3, data representative of two independent 
experiements. Statistical analysis was performed using an unpaired two-tailed student’s t 
test. Error bars denote SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
The suppression of ABM proliferation by Treg cells in the presence of TRCs was 
enhanced by the addition of exogenous IL-7 (Fig. 23).  
 
Figure 23. IL-7 stimulation enhances Treg-mediated suppression of ABM cells on 
TRCs. (A) Proliferation of eFluor670 stained ABM cells measured after 5 days of anti-
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CD3/CD28 beads activation in vitro without hrIL-2. ABM cells were cultured alone (black) or 
together with Treg cells in a 2:1 situation (red) without any additional stimulation or with 
50ng/ml IL-7 (ABM, blue and 2:1, green). (B) Proliferation presented as MFI of proliferation 
dye eFluor670. Data are represented ad median with interquartile range. n = 4. Statistical 
analysis was performed using an unpaired two-tailed student’s t test. **, P < 0.01; ***, P < 
0.001. 
4.12   Contribution of IL-7 to Treg-mediated tolerance 
To show the effect of IL-7 in the establishment of Treg-mediated tolerance, we injected 
2:1 bm12-transplantated mice with IL-7 complex generated with IL-7 and the anti-IL-7 Ab 
M25. We used IL-7 complex instead of IL-7 alone because it was shown to increase the 
life span and enhance the biological activity of IL-7 in vivo (152), as it was reported for the 
IL-2 complex (153). Treated mice did not increase in counts (Fig. 24, A) and frequency of 
Treg and ABM cells (data not shown) and rejected the skin graft within 16 days similar to 
PBS control (Fig. 24, B). In addition, IL-7R down-regulation and CD25 up-regulation were 
not detected in either Treg cells or ABM cells (data not shown).  
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Figure 24. IL-7 complex injection does not promote tolerance in 2:1 mice. (A) Counts of 
Treg cells (left) and ABM cells (right) found in the skin dLN of allograft transplanted Rag2-/- 
mice adoptively transferred with 2:1 Treg:ABM cells ratio and treated with IL-7-complex 
(formed with 1µg mrIL-7 and 5µg M25 Ab per mouse) or with PBS. Mice were treated 
starting from day 0 for 5 times at 3 days interval. (B) Graft survival is displayed as Kaplan-
Meier plot. The difference between the groups is not statistically significant using Log-rank 
(Mantel Cox) test. 
Consequently, we blocked IL-7 expression by injecting the anti-IL-7 Ab M25 (154) (47). IL-
7 blocking treatment started before (day -3) or after (day 6) adoptive T cells transfer 
induced graft rejection in 1/6 and 2/6 10:1 mice respectively until day 21 (Fig. 25). At day 
21 mice were sacrificed to analyze the T cells phenotype. Both Treg cells and ABM cells 
were only slightly decreased in numbers and the expression of IL-7R and CD25 was 
similar to PBS control. These data suggest that addition or blocking of IL-7 in vivo does 
not affect Treg counts, CD25 expression and Treg-mediated tolerance. This is 
inconsistent with the in vitro data, however may reflect specific in vivo issues such as 
successful delivery to the LNs and persistence there.  
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Figure 25. Blocking IL-7 does not inhibit tolerance in 10:1 mice. Allograft transplanted 
Rag2-/- mice adoptively transferred with 10:1 Treg:ABM cells ratio and treated with anti-IL-7 
Ab M25 (0.5µg/kg) or PBS (n = 6). One treatment started 3 days before (n = 6) or 6 days (n = 
6) after adoptive T cells transfer for 5 times at 3 days interval. Graft survival is displayed as 
Kaplan-Meier plot. The difference between the groups is not statistically significant using 
Log-rank (Mantel Cox) test. 
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5 Discussion 
Successful organ transplantation depends on the establishment of tolerance to non-self 
antigens. To reach this goal patients must undergo long-term treatment with 
immunosuppressive drug combinations, which penalize the entire immune system and 
inflict many unwanted side effects including an increased risk of infections and tumors. It 
is therefore of primary importance to design new treatments which favor the development 
of allo-antigen specific tolerance. Nowadays, two main tolerizing protocols are being 
tested in clinical trials: 1) blocking the activation of Ag-specific T cells by injection of 
antibodies against co-stimulatory molecules and 2) transfusion of ex vivo expanded Treg 
cells. Mice tolerant to skin grafts through co-receptor blockade contain Treg cells within 
the allograft, which prevent graft rejection. Treg cells have been shown to convert naïve T 
cells into tolerant cells in a process known as infectious tolerance (155). Although many 
mouse models have been generated to study allograft tolerance, recipient mice must be 
continuously treated with specific depleting agents or co-stimulation blocking antibodies 
to achieve long-term tolerance. These treatments have many non-specific effects, which 
make results difficult to interpret. Moreover, specific cell-cell interactions are difficult to 
study due to various parameters changing during the transplant rejection process.  
Our animal model has the advantage to dissect in vivo the activity of different cellular 
component, like Treg, dendritic cells, effector T cells and stroma cells at different time 
points. CD4 T cells (ABM cells), recognizing the bm12 mutation in the antigen presenting 
groove of the MHC class II molecule, generate an alloresponse against a major MHC 
mismatched antigen and cause graft rejection. The cotransfer of polyclonal Treg cells in 
combination with naïve bm12-specific CD4 effector T cells (ABM cells) allowed us to 
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investigate the immunomodulatory function of Treg cells and their interaction with other 
cells at the site of graft rejection and T cells priming. We were able to show that 10 times 
more Treg cells induce 100% survival of the skin graft, while the injection of lower ratios 
delayed the rejection.  
First, we characterized the migration of Treg cells and effector T cells to the skin graft, 
since Treg cells were previously shown to infiltrate to and persist in the graft during the 
establishment of tolerance (156). Using our model, we demonstrated that both Treg and 
ABM cell populations in the skin graft express CCR4, suggesting a directed migration to 
the inflamed skin. Nevertheless, re-transplantation of short-term tolerated grafts on 
immunocompetent C57BL/6 mice did not result in graft tolerance and graft rejection was 
not correlated with the presence of Treg cells in the skin, since similar numbers were 
detected in the graft of the 2:1, 5:1, 10:1 and Treg groups. These data indicate that 
tolerance is established in the draining LNs rather than in the peripheral tissue (157, 158).  
In order to develop and suppress allograft rejection Treg cells need to occupy the LNs 
(159). In agreement with this, high numbers of Treg cells were present in the dLNs of 
transplanted mice. Higher numbers of adoptively transferred Treg cells resulted in lower 
numbers of effector ABM cells in the LNs. By calculating the ratio of Treg to ABM cells in 
the LNs on day 9, we found that a ratio higher then 1 delayed rejection (5:1 group) while a 
ratio higher then 2 (10:1 group) correlates with long-term tolerance.  
One mechanism by which Treg cells might impair the activation and proliferation of ABM 
cells is by influencing the activation state of DCs (160). Isolation of CD11chigh DCs from 
the dLNs of transplanted mice with or without different T cells ratios (ABM, 10:1) did not 
induce activation, proliferation or cytokine release by ABM cells in vitro (own data). 
However, in vivo analysis showed that donor bm12-DCs were not impaired in migration to 
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the dLNs and in the expression of costimulatory molecules, indicating that Treg cells do 
not inhibit direct antigen presentation by inducing a tolerogenic phenotype. 
Treg cells were previously shown to suppress T cell responses by inhibiting activation and 
proliferation of effector T cells in various animal models (161, 162). Our data reveal that 
although Treg cells do not alter the expression of activation molecules like CD25, CD44 
and PD-1, they still impair the proliferation and the cytokine release of effector ABM cells. 
Higher Treg:ABM ratios in the LNs of bm12-transplanted mice prevented effector T cell 
function independent of DC activation.  
Next, we wondered whether Treg survival is sustained in the LN and whether the Treg-
mediated suppression might alter the LN environment.  
Because of the recent discovery of TRCs in modulating IFN-γ mediated T cell responses 
(105), there is a lack of knowledge about TRCs cell biology. Therefore, we studied the 
function of TRCs during Treg mediated tolerance to MHC class II mismatched skin grafts. 
TRCs have the potential to inhibit the proliferation of CD8 T cells via nitric oxide (NO) 
release (104, 120) or PD-L1 surface expression (104, 120) in response to IFN-γ. In our 
assays we characterized the effect of IFN-γ/IFN-γR signaling on TRCs and found that they 
up-regulated transcription of NOS2, NOS3, IAb, PD-L1, ICAM-1 and VCAM-1. These 
findings are in agreement with published observations. In addition, we demonstrated that 
increased transcription correlated with increased surface expression of IAb, PD-L1 and 
ICAM-1 on TRCs. The higher transcription of ICAM-1, VCAM-1, IAb, IL-7, TSLP and PD-
L1 on TRCs isolated from allograft-transplanted compared to syngraft-transplanted mice in 
C57BL/6 mice suggested a dependency on IFN-γ signaling. Indeed, the absence of IFN-γ 
signaling in IFN-γ-/- and IFN-γR-/- mice (own data) abolished the differences in gene 
transcription seen during allo-responses, suggesting that IFN-γ is the main modulator of 
TRCs activity during acute alloresponses in immunocompetent mice. NOS transcripts were 
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not significantly different during acute alloresponses, suggesting that other mediators, 
including TNF and IL-1β, contributed to the release of nitric oxide (own data and (104, 
120)).  
To address whether T cells might influence the biological activity of LNSCs under steady 
state conditions we analyzed the transcriptional profile of TRCs in T cell deficient mice. 
The transcriptional profile of Rag2-/- and CD3e-/- TRCs was not different compared to 
C57BL/6 TRCs and the number of TRCs was similar in all strains, suggesting that the 
presence of T cells under non-inflammatory conditions does not induce expansion of TRCs 
and remodeling of the LN. The higher expression of IAb on the surface of C57BL/6 TRCs 
indicates an important role for T cells homeostasis (150). In summary, T cells have only a 
minor impact on TRCs activity under steady state conditions, while inflammatory stimuli 
and T cell activation can lead to modulation of TRCs activity.  
Since Treg cells downregulate IFN-γ production by ABM cells, we hypothesized that Treg-
mediated tolerance might influence the TRC compartment. Indeed, uncontrolled IFN-γ 
responses during viral infections have been shown to induce LNSCs damage (98, 112, 
117, 163). However, Treg-mediated suppression of IFN-γ response did not change 
composition and proliferation of LNSC during alloresponses.  
The major functions of LNSC are the release of chemokines that promote the recruitment 
of immune cells to the LN and the provision of survival factors for naïve and activated T 
cells. As several groups have described, CCL19 and CCL21 are the main chemokines to 
attract CCR7 expressing DCs and T cells to the LNs (164). CCR7 is not only important for 
recruitment, but also for the intranodal mobility inside the LNs (107, 108). Moreover, Treg 
cells require LN occupancy and CCR7 signaling for their activation and function (158). The 
expression of CCR7 on both ABM cells and Treg cells was similar in all groups, but Treg 
cells are required to maintain the transcription of CCL19 and CCL21 in TRCs. We 
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hypothesized that this contributes to Treg cell occupancy of the LNs and suppression of 
effector responses at the 10:1 ratio. However, lower numbers of transferred Treg cells 
were unable to block graft rejection by preventing down regulation of CCL19 and CCL21 in 
TRCs isolated from the 2:1 group. In this case, the resultant high numbers of Treg cells 
might therefore be a consequence of Treg expansion driven by IL-2 released from 
activated ABM cells.  
Inflammatory cytokines up-regulate adhesion molecules on the surface of LECs, including 
ICAM-1 and VCAM-1 (95, 165-167). In the LNs, ICAM-1 and VCAM-1 are expressed on 
the surface of TRCs, HEVs and resident DCs (95, 97, 101, 168). Interestingly, ICAM-1 and 
VCAM-1 transcripts were increased in the TRCs isolated from tolerogenic 10:1 mice, but 
surface expression of ICAM-1 was only slightly increased and VCAM-1 was rather 
downregulated by the presence of Treg cells. The downregulation of VCAM-1 could be a 
consequence of Treg-mediated suppression (169) of IFN-γ release. The upregulation of 
ICAM-1 might be dependent on the presence of other cytokines, like TNFα. In fact, Treg 
cells were shown to inhibit Th1 responses by impairing IFN-γ but not TNFα production 
(161). Whether interaction of ICAM-1 and VCAM-1 on TRCs with LFA-1 and VLA-4 on 
Treg cells respectively might influence suppression was not addressed. Since upregulation 
of ICAM-1 is restricted to the 10:1 group, we can speculate that it might support the 
suppression of T cells since it was shown that the majority of Treg cells express LFA-1 in 
the LNs, which increases their suppressive capacity in vivo (170). In addition, the 
expression of ICAM-1 on TRCs might lead to the adhesion of CD11b+/Mac-1+ DCs (171, 
172), which can drive mature DCs to differentiate into regulatory DCs. The tolerogenic 
phenotype of DCs in vitro might be a consequence of their increased interaction with 
stromal cells. Changes in the interactions of DCs and T cells with TRCs in vivo might 
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influence their activity by the local upregulation of adhesion molecules and the release of 
cytokines. 
TSLP was highly produced by TRCs in the 10:1 group, suggesting that Treg cells might 
need TSLP during Treg-mediated tolerance. In the periphery, TSLP is mainly described to 
be involved in the generation of Th2 responses by modulating DCs (16-18, 58). The 
release of TSLP by human thymic epithelial cells activates a subpopulation of DC to 
express CD80 and CD86, which may be critical for the differentiation of auto-reactive T 
cells into Treg cells (59). However, the role in the maintenance and function of Treg cells 
in the periphery remains unknown. 
In addition to TSLP, the transcription of the analogue cytokine IL-7 was enhanced in the 
10:1 group. We hypothesized that stronger adhesion of T cells to TRCs might facilitate T 
cell access to this survival factor. IL-7 was induced following the activation of allogenic T 
cells in transplanted C57BL/6 mice and by TNFα alone or in combination with IFN-γ in vitro 
(own data). Since Treg cells only partially suppress IFN-γ release (own data) and are 
unable to shutoff TNFα (161), TRCs might respond by induction of IL-7 transcription. The 
lower IL-7 transcripts levels in the ABM and 2:1 group on day 9 might be the result of a 
different kinetic of effector cytokine release. Hence, preliminary data suggests that 
despite the absence of T cells in the LN on day 3, IL-7 transcription in the ABM group 
was induced in TRCs. In the future we plan to examine IL-7 production in the 10:1 group 
by transplanting IL-7-hCD25 mice, which express the human CD25 protein under the IL-7 
promoter (117, 173). This mouse would allow us to detected even small amounts of 
produced IL-7 by staining the hCD25 protein. 
Treg cells in the 10:1 group downregulate not only the IFN-γ, but also the IL-2 production 
of ABM cells in vitro. In addition, Treg cells were shown to downregulate the IL-2 mRNA on 
responder CD4 T cells after IL-2 signaling (174). The fact that IL-2 production by T cells in 
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the periphery is transient and Ag-dependent (175) might explain the low numbers of both 
ABM and Treg cells in the LN of syngrafted Rag2-/- mice. Accordingly, high Treg numbers 
were recovered in the 2:1 but not in the 10:1 group of allotransplanted mice underscoring 
the IL-2 dependence of Treg cells in homeostasis and activation (84). New data provide 
evidence that IL-7 can help Treg cell homeostasis in the periphery in the absence of IL-2 
(83). In our transplantation model, the increased transcription of IL-7 by TRCs might 
improve Treg survival and maintenance of graft tolerance.  
IL-7R is downregulated after activation on conventional T cells, as a consequence of the 
IL-2 released from activated T cells (176), and is reexpressed on memory T cells (54, 177). 
Lower expression of IL-7R on Treg cells isolated from the 10:1 and Treg group on day 6 
indicates signaling after release of IL-7 from TRCs rather than IL-2 from ABM cells.  
Although our results do not rule out the possibility of an additional mechanism for IL-7R 
down-regulation, IL-7 recognition by Treg cells leads to down-regulation of IL-7R and 
STAT5 phosphorylation in naïve Treg cells. Since, CD3-activation of Treg cells in the 
absence of exogenous IL-2 also showed down-regulation of IL-7R, it is possible that IL-7 
signaling can still occur. Treg cells survived better in the presence of IL-7 in vitro and 
exhibited higher levels of the IL-2Rα chain CD25, similar to the 10:1 situation in vivo. In 
addition, suppression assays in vitro showed that Treg cells were enhancing their 
suppressive capacity on ABM proliferation. These data suggest that IL-7 signaling might 
influence the ability of Treg cells to bind IL-2 produced by activated T cells. Increased 
surface expression of CD25 in Treg cells would result in sensitization to low concentration 
of IL-2 by better capturing free IL-2, as shown for activated CD25+ T cells (178). However, 
IL-2Rα alone binds IL-2 with low affinity without signal transduction and by presenting it 
to the IL-2Rβ and γc forms a high affinity IL-2R complex (179). It would be interesting to 
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investigate whether IL-7 also induces the up-regulation of IL-2Rβ and γc chains resulting 
in a high affinity binding of IL-2 and signal transduction. As a consequence, Treg cells 
could increase sequestration of IL-2 produced by effector T cells. Thus, Treg suppression 
of ABM proliferation in the presence of IL-7 was increased in vitro.  
Activation of Treg cells in the presence of IL-2 and TCR signaling can lead to expansion 
of a population of highly suppressive short lived cells expressing TIM-3 and often PD-1 
(90). IL-7 stimulation during Treg activation in vitro did not induce and modulate the IL-2-
dependent TIM-3 up-regulation. These findings suggest that the higher surface 
expression of TIM-3 on Treg cells from the 2:1 and 10:1 groups might be a consequence 
of IL-2 signaling. Whether the high level of IL-7 in the 10:1 group increases the survival of 
short lived Treg cells is currently under investigation. However the over stimulation or 
blocking of the IL-7 pathway in vivo was not influencing the rejection or the Treg-
mediated tolerance establishment.  
Taken together, our data show that Treg cells suppress the activation and IFN-γ release 
by effector T cells and modulate the TRCs to release IL-7, which might be important for 
suppressing skin graft alloresponses by maintaining high numbers of Treg cells in the 
LNs. Moreover IL-7 sensitizes and might facilitate the recognition of IL-2 to induce 
expansion better and suppression of effector T cells. 
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